Pertti J. Neuvonen

[vc_row][vc_column width=”1/4″]neuvonen
[/vc_column][vc_column width=”3/4″]

Professor Pertti J. Neuvonen, MD, Finland

Professor Neuvonen is widely recognized for his outstanding contributions in the field of drug interactions, one of the fundamental areas of clinical pharmacology practise and individualized drug therapy. Already in the 1970s, he identified the clinically significant interactions of tetracyclines with iron and other two valent cations, and already by the 1980s, he had identified numerous interactions affecting the absorption of drugs. Thereafter, since the late 1980s, his research group has identified and characterized exceptionally many clinically important drug-drug interactions based on inhibition or induction of drug metabolizing enzymes or transporter proteins. These include interactions of many commonly used drugs, e.g., lipid-lowering drugs, cardiovascular drugs, glucocorticoids, antimicrobial agents, antidiabetic drugs, antiasthmatic drugs, analgesics, anticancer agents and psychotropic drugs. Often his work has included well-targeted in vitro studies, pharmacogenetic approaches or time- and dose-dependency studies, aiming to clarify the mechanisms of the interactions, whether occurring via drug metabolism or transport.
[/vc_column][/vc_row]

[vc_row][vc_column]
[wm_tabs active=”1″ ]

[wm_item title=”Nomination Letter”]

Highlights:

  • Highly cited researcher in Pharmacology and Toxicology (ISIHighlyCited.com) since 2005
  • Hirsch-index 74
  • About 515 original articles (almost 100 published in Clinical Pharmacology & Therapeutics)
  • Known worldwide for his groundbreaking studies on use of activated charcoal to treat poisonings and for his systematic studies concerning drug-drug interactions (probably the most important area of expertise in the daily clinical pharmacology routine)
  • Supervised more than 40 clinical pharmacologists and PhD theses, including five, who have already reached professorship

To Members of the EACPT Council,

We are nominating Professor emeritus Pertti J. Neuvonen (born August 25, 1943) for the 2017 EACPT Lifetime Achievement Award in Clinical Pharmacology. Pertti J. Neuvonen has dedicated his working life for the benefit of the science and specialty of clinical pharmacology. He is still active, although he retired in August 2011 from his position as the Professor and Chairman of Clinical Pharmacology at the University of Helsinki, Finland.

Professor Neuvonen is widely recognized for his outstanding contributions in the field of drug interactions, one of the fundamental areas of clinical pharmacology practise and individualized drug therapy. Already in the 1970s, he identified the clinically significant interactions of tetracyclines with iron and other two valent cations, and already by the 1980s, he had identified numerous interactions affecting the absorption of drugs. Thereafter, since the late 1980s, his research group has identified and characterized exceptionally many clinically important drug-drug interactions based on inhibition or induction of drug metabolizing enzymes or transporter proteins. These include interactions of many commonly used drugs, e.g., lipid-lowering drugs, cardiovascular drugs, glucocorticoids, antimicrobial agents, antidiabetic drugs, antiasthmatic drugs, analgesics, anticancer agents and psychotropic drugs. Often his work has included well-targeted in vitro studies, pharmacogenetic approaches or time- and dose-dependency studies, aiming to clarify the mechanisms of the interactions, whether occurring via drug metabolism or transport.

Overall, Neuvonen’s findings have paved the way to understanding the mechanisms of drug interactions related to the absorption, biotransformation and transport of drugs and to predict these interactions on the basis of experimental in vitro studies. In addition to directly improving patient care, and being commonly cited in textbooks, drug interaction databases and treatment guidelines, the findings of his systematic research efforts have profoundly affected the principles and guidelines applied in drug development. In drug-drug interaction guidelines, many of the recommended cytochrome P450 enzyme probe substrates and inhibitors, such as midazolam and itraconazole for CYP3A4 and repaglinide and gemfibrozil for CYP2C8, are based largely on his pioneering studies. As a result, drug interactions can now be predicted and identified already at an early stage of drug development.

During his career, Professor Neuvonen has made ground-breaking research also in the area of acute poisonings, antidotes and adverse drug reactions. His studies on oral activated charcoal have been of pivotal importance for the implementation of the routine use of activated charcoal in the treatment of oral poisonings during the 1990’s. For his studies on drug interactions and activated charcoal, he was selected as Drug Absorption Foundation Lecturer in 1993 (Edinburgh, UK).

Professor Neuvonen has published about 515 original articles (of these, about 20% have been published in Clinical Pharmacology & Therapeutics), and 180 review articles or textbook chapters, The outstanding scientific quality of his work is reflected by the high number of citations to his articles in the scientific literature. His Hirsch-index is 74, the total number of citations to his publications is more than 20 000 (October 2016), and he is one of the most highly cited pharmacologists in the world (ISIHighlyCited.com, since 2005). The first BCPT Nordic Prize in Basic & Clinical Pharmacology & Toxicology was awarded in 2011 to Professor Neuvonen as a recognition of his outstanding scientific merits.

On a national level, Professor Neuvonen is distinguished for his unwavering pioneering work to improve possibilities for clinical drug research, to educate clinical pharmacologists and to develop the specialty of clinical pharmacology. He was one of the founders and the first chairman of the Finnish Society of Clinical Pharmacology (founded in 1994). He was the founder and director of the national Clinical Drug Research Graduate School, which was active in 1995-2015 and is one of the main foundations of the national doctoral education network FinPharmaNet, which was launched in 2016.

Neuvonen has supervised more than 40 PhD doctoral theses and is still now supervising or co-supervising several doctoral students. For his exceptionally meritorious work in educating medical researchers in Finland, he has received the national Lauri Saxen prize in 1997 and the Maud Kuistila prize in 2003. Apart from these prizes, five of his students have themselves achieved professorships (Olkkola, Kivista, Niemi, Backman, Xiang), which is perhaps the best evidence for the strength of his “shoulders” and high quality of his mentorship. Moreover, he has been the chief editor of the Finnish textbook in clinical pharmacology and therapeutics, which has been published in 1994, 2002 and 2011. Since 1998, he has been a member of the Finnish Academy of Science and Letters.

Regardless of his remarkable scientific contributions, Professor Neuvonen is a modest, down-to-earth person, who has dedicated his life to science, mentorship and clinical responsibilities. He is characterized by logical, crystal clear scientific thinking, perseverance, and a continuous enthusiasm for new knowledge of clinical importance. In addition to these characteristics, his success is based on thoughtful leadership and the ability to promote a creative research environment, which allows young scientists to fully engage in a productive scientific work. Distinctive of his clinical research, his studies have been systematic and often very elegant and mechanistic, providing insights into enzymes and transporters that are involved in clinically important drug-drug interactions.

We the undersigned propose that the 2017 EACPT Lifetime Achievement Award in Clinical Pharmacology will be awarded to Professor emeritus Pertti J. Neuvonen for his life-long, outstanding and widely recognized merits in clinical pharmacology, which have had a tremendous scientific and clinical impact. The accompanying curriculum vitae and list of publications will demonstrate the highest esteem that Pert J. Neuvonen holds among the world’s leading clinical pharmacologists.

Respectively submitted,
Mikko Niemi, M.D., Ph.D., Chair, Finnish Society of Clinical Pharmacology
Professor of Pharmacogenetics
Department of Clinical Pharmacology, University of Helsinki Tukholmankatu 8C, FI-00290 Helsinki, FINLAND

I concur,
Janne Backman, M.D., Ph.D., EACPT Council Delegate, Finnish Society of Clinical Pharmacology
Professor in Clinical Pharmacology and Individual Medicine Department of Clinical Pharmacology,
University of Helsinki FINLAND

I concur,
Miia Turpeinen, M.D., Ph.D., EACPT Council Delegate, Finnish Society of Clinical Pharmacology Senior medical officer, Assistant professor
Oulu University Hospital and University of Oulu FINLAND

I concur,
Marja-Liisa Dahl, MD, PhD, Professor of Clinical Pharmacology
Department of Laboratory Medicine, Division of Clinical Pharmacology Karolinska Institutet, Stockholm SWEDEN

I concur,
Matthias Schwab, MD, PhD, Professor and Chair of Clinical Pharmacology
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, GERMANY

view original nomination letter

[/wm_item]

[wm_item title=”Curriculum Vitae”]

Personal Details

Professor Pertti Jaaki Neuvonen, M.D.,
born 25 August 1943 (Kirvu, Finland),
Married, 5 children
Researcher ID: G – 4675 – 2011

Education and Training
1962 Matriculation examination
1962-63 Military Service (obligatory), rank, second lieutenant
1970 Licentiate of Medicine (MD), University of Helsinki
1970 Licensed physician
1971 Doctor of Medical Sciences (PhD), University of Helsinki
1972 Title of Docent (“Senior Lecturer competence”) in Pharmacology, Univ. Helsinki
1977 Specialist Degree in Clinical Pharmacology
Current Position
since 1. Sept. 2011 Emeritus Professor of Clinical Pharmacology
2011- Researcher, University of Helsinki, Dept. Clinical Pharmacology
Previous Professional Appointments
1971-72 University of Helsinki, Department of Pharmacology, Tutor, 1966 -1969; Lecturer 1970 Hannover Medical School, W-Germany, Fellow of A. v. Humboldt-Foundation
1972 U. Helsinki, Dept. Pharmacy, Assoc. Prof. Pharmacol. Biolog. Standardizaion of Drugs
1972-1985 U. Helsinki and HU Central Hospital, Dept. Clinical Pharmacology, Assistant Professor/Senior Lecturer/Consultant of Clinical Pharmacology, incl. Poison Inform. Cntr.
1976 HU Central Hospital, Dept. Internal Medicine, Resident
1985-1988 U. Helsinki and HU Central Hospital, Dept. Clinical Pharmacology, Acting Professor and Head Physician of Clinical Pharmacology
1988-1991 U. Turku (Finland), Dept. Pharmacology, Professor & Chairman
1992-2011 U. Helsinki and HU Central Hospital, Dept. Clinical Pharmacology, Professor & Chairman, and Head Physician
Supervisor of Doctoral (PhD) Dissertations
Official supervisor, alone or jointly with another supervisor, of 44 Doctoral (PhD) thesis projects at the University of Helsinki or Turku. In addition, a mentor and coauthor in about 20 other PhD projects. Of his former Doctoral students, Professors Klaus Olkkola, Kari Kivistö, Janne Backman, Mikko Niemi and Xiang Xiaoqiang have gained a university professorship.
Reviewer for Professorships
1992-1993 Århus University, Denmark: Professor in Clinical Pharmacology
1991 Jordan Univ. Science and Technology: Assoc. Professor in Pharmacology
1994, 1995 Odense University, Denmark: Professor in Human Pharmacology
2001-2002 and 2007 University of Helsinki, Finland: Professor in Pharmacology
2010 University of Turku, Finland: Professor in Pharmacology
Editorial Board Memberships
Clinical Pharmacokinetics, Eur J Clin Pharmacol, Int J Clin Pharmacol Ther, Brit J Clin Pharmacol, Current Diabetes Reviews
Scientific Positions of Trust and Administrative Tasks
1975 – 2006 Government’s Advisory Board on Pharmaceutical Services, Expert Member
1987 – 2007 Ministry of Social Affairs & Health, National R&D Centre, Clin. Pharmacol. Advisor
1996 – 2010 Social Insurance Institute, social medicine and drug committees, Member
1976 – 87, 1993-2016 Helsinki Univ. Central Hospital, Drug Advisory Board, Expert Member
1993 – 1999 Univ. Helsinki/ HU Central Hospital, Ethics Committee, Member (1993-99), Chairman (1997-99)
2000 – 05 Hospital District of Helsinki & Uusimaa, Coordinating Ethics Comm., Member & Chair
1994 – 98/2003-08 U. Helsinki, Med. Faculty, Clinical Med. Instit., Board member(1994-98, 2003-08), deputy chair (2006-08)
2002 – 11 U.Helsinki, Med. Faculty, Clinical Med. Instit., Chairm. of the Diagnostic-Therap. Dept.
1995 – 2011 Finnish Academy of Science & Letters, Member 1998–, Secretary of the Medical group 2005-8 Finnish Clinical Drug Research Graduate School, Founder, and Director
1977 – 1985 Finnish Pharmacological Society, Board member and Secretary 1
1994 – 2008 Finnish Society for Clinical Pharmacology, Board member 1994-2008, Chairman 1994-2000
German Society for Experimental and Clinical Pharmacology and Toxicology, Member British Pharmacological Society, Member
1996-2002 European Association of Clinical Pharmacology and Therapeutics, Delegate
Awards
The Drug Absorption Foundation Lecturer (Edinburgh) 1993
The Lauri Saxén prize (U. Helsinki) 1997 ”for distinguished activities in educating researchers” The Maud Kuistila prize (Finland) 2003 ”to a distinguished instructor of medical researchers” ISI HighlyCited (pharmacology), in 2005, 2008, 2015, 2016 (ThomsonReuters)
The BCPT Nordic Prize in Basic & Clinical Pharmacology & Toxicology, 2011 FDA Office of Clinical Pharmacology (USA) medal, 2011
Honorary Member of the Finnish Society for Clinical Pharmacology, 2011

Hirsch Index: 74 (Web of Science, Oct. 2016)
Number of citations: about 21 000.

Textbook in Clinical Pharmacology and Drug Therapy (Kliininen Farmakologia ja Lääkehoito) – Chairman of the Editorial board (and a writer of several chapters) of the Finnish textbook for medical students and clinicians:

  • 1994 (1. ed., 800 pages)
  • 2002 (2. ed., 1067 pages)
  • 2011 (3. ed., 1032 pages)

Research topics

Prof. Neuvonen´s Research topics include several aspects of Clinical Pharmacology, e.g. Clinical Pharmacokinetics, Drug Metabolism and Transport, Drug-Drug Interactions, Food- Drug Interactions, Pharmacogenetics, Effect of Diseases (liver cirrhosis, renal failure, migraine attacks) on Pharmacokinetics, Clinical Toxicology, Acute Intoxications, Adverse Effects, Pharmacoepidemiology, etc.

Detection and exploration of previously unrecognized drug interactions and adverse effects (1970-2016).

Neuvonen published his first drug-drug interaction studies already in the early 1970s, e.g.,
“Interference of iron with the absorption of tetracyclines in man” (Neuvonen et al., BMJ 1970). This study prompted The Leading Acticle in BMJ, because, at that time, oral tetracyclines and iron preparations were commonly administered to patients with chronic infections. In addition, he also showed that, doxycycline elimination rate was clearly increased in the patients, who used barbiturates (Neuvonen and Penttilä, BMJ 1974) or other inducing antiepileptics, e.g., carbamazepine (Penttilä et al., BMJ 1974), thus increasing the risk of subtherapeutic antibiotic concentrations.

CYP3A-mediated drug interactions. Neuvonen and his co-workers have and published nearly 70 studies on the CYP3A4-mediated drug interactions, since the early 1990s. Their findings have uncovered, e.g., that itraconazole (and ketoconazole) can cause potentially hazardous interactions with, e.g., midazolam, triazolam, buspirone, terfenadine, dexamethasone, methylprednisolone, budesonide, lovastatin, simvastatin, atorvastatin, quinidine, digoxin, felodipine, oxycodone and buspirone. The mechanism of these interactions usually is either the inhibition of CYP3A4/5 enzyme, or of P-glycoprotein transporter (as in the case of digoxin), or both. The group has characterized also the effects of the doses and routes of administration of victim and perpetrator drugs on the extent of interaction, as well as the duration of the interaction potential.

These findings, which later have been confirmed by many other groups, were in a strong discrepancy with the product information of Sporanox, which in 1992 stated that itraconazole does not inhibit drug metabolism. Today, itraconazole is the recommended probe inhibitor for CYP3A-mediated interaction studies, e.g., in the guidelines of FDA for drug industry. Itraconazole and ketoconazole cause only moderate or minor interactions with prednisolone, pravastatin, zopiclone, zolpidem, morphine, tramadol, ketamine or tzafirlukast. In addition, our group has demonstrated many potential drug interactions caused by fluconazole, voriconazole and miconazole.

After we had found that simvastatin, lovastatin, buspirone, midazolam, and triazolam are sensitive and selective substrates of CYP3A4, we could use these drugs as probes in our further studies, in which the CYP3A-mediated interaction potential of suspected perpetrators were studied in healthy volunteers using standardized conditions and in patients, who used inhibitors or inducers. Thus, we could determine the interaction potential of many perpetrators such as erythromycin, roxithromycin, azithromycin, chlarithromycin, diltiazem, verapamil, saquinavir, imatinib, grapefruit juice, rifampicin, carbamazepine and St. John Wort, with CYP3A4 substrate drugs. The results of these studies have been published in more 100 papers between 1993-2016.

Interaction potential of fruit juices. Neuvonen and his co-workers have studied the pharmacokinetic effects of fruit juices since the 1990s. They have found that grapefruit juice can markedly, even up to 5-10-fold, increase the AUC of many orally ingested drugs (e.g., buspirone, ketamine, oxycodone, simvastatin, lovastatin, atorvastatin, cisapride and ticagrelor (by inhibiting intestinal CYP3A). In contrast to these effects, grapefruit juice, apple juice and orange juice can markedly decrease the AUC of, e.g., celiprolol (Lilja et al., 2003) and aliskiren (Tapaninen et al., 2010) by reducing their transporter-mediated absorption.

Furthermore, grapefruit juice may inhibit the metabolic activation of clopidogrel and prasugrel (Holmberg et al., 2014; 2015).

Statin interactions. Neuvonen and his group discovered in the 1990s, that inhibitors of CYP3A4 can greatly (up to 10-20-fold) increase plasma concentrations of lovastatin, simvastatin and of their active acid forms. The effect on atorvastatin was somewhat smaller. The inhibition of CYP3A4 explained the increased muscle toxicity of these statins caused by, e.g., azole antimycotics, erythromycin derivatives, verapamil and diltiazem, but not the increased toxicity of statins caused by gemfibrozil. We could then show that gemfibrozil increased plasma concentrations of lovastatin acid and of simvastatin acid but not of their parent lactones. This effect of gemfibrozil on statins is mainly caused by an inhibition of the OATP1B1-mediated hepatic uptake, which increases their plasma exposure and muscle toxicity (Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. CPT 2006:80:565-81). The increased muscle toxicity of gemfibrozil-cerivastatin combination has even a more complex mechanism, because its main perpetrator is the glucuronid metabolite of gemfibrozil, which is an inhibitor of both CYP2C8 and OATP1B1.

CYP2C8 in drug metabolism. During the latest 15 years, Prof. Neuvonen, together with his former PhD students and todays Professors Janne Backman and Mikko Niemi, has extensively studied the role of CYP2C8 in the metabolism of drugs, CYP2C8-mediated drug interactions, and inhibitors of CYP2C8. They could identify many generally used drugs, which are mainly metabolized by CYP2C8, or which are potent inhibitors of this enzyme. The interaction potential of these drugs had not been recognized earlier, even though some of them had been in clinical use for decades. CYP2C8 is responsible for the metabolism and elimination of, e.g., cerivastatin, repaglinide, rosiglitazone, pioglitazone and montelukast. Gemfibrozil and clopidogrel, mainly via formation of their glucuronid- metabolite, are potent inhibitors of CYP2C8. Our observations explain the high risk of, often fatal, muscle toxicity associated with the combined use of cerivastin and gemfibrozil (and of clopidogrel), which led to the withdrawal of cerivastatin from the market in 2001. Similarly, gemfibrozil and clopidogrel can markedly increase the risk of hypoglycaemia when used with repaglinide. These studies on the role of CYP2C8 in drug metabolism and interactions have been published since 2002 in about 40 original papers, and recently reviewed (Backman et al., Pharmacol. Reviews, 2016).

OATP1B1 and other membrane transporters in pharmacokinetics and drug interactions. Together with Professor Niemi and other co-workers, Prof. Neuvonen has studied the significance of OATP1B1, BCRP and some other membrane transporters in the pharmacokinetics and interactions of drugs, e.g., statins. Furthermore, the group has investigated the effect of genetic polymorphisms in membrane transporters on individual differences in pharmacokinetics. In particular, the OATP1B1 has been in focus (Niemi M, Pasanen MK, Neuvonen PJ: Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol. Reviews 2011).

Tizanidine and CYP1A2. Tizanidine had been in clinical use for two decades until Neuvonen´s group discovered that tizanidine nearly exclusively is eliminated by CYP1A2, and that inhibitors of this enzyme drastically increase its plasma concentrations causing potentially life-threatening adverse effects. Fluvoxamine increased the mean AUC of tizanidine more than 30-fold, and ciprofloxacin increased tizanidine AUC more than 10-fold. Tizanidine caused a strong hypotension when ingested with fluvoxamine or ciprofloxacin but not when taken alone (Granfors et al., 2004 x 3).

Acute intoxications can uncover unrecognized properties of drugs. Two cases of sotalol intoxication, admitted to the Helsinki University hospital demonstrated for the first time in humans that sotalol prolongs the QT-interval and can cause life-threatening cardiac arrhythmias (Neuvonen et al., 1979). This beta-blocking agent had been in clinical use for nearly 10 years in many countries. In clinical trials, sotalol had been used in huge doses (several grams/day) without any comments on its QT-prolonging or cardiotoxic property. Soon after the publication of these two cases of sotalol intoxication, many similar cases were found in Finland and elsewhere. We could show that also therapeutically used high sotalol doses were associated with considerably prolonged QT-interval and risk of torsade de pointes, thus confirming the earlier unrecognized fact that sotalol is a “different” beta-blocking agent (Neuvonen et al., CPT 1982).

In 1992, five fatal cases of acute serotonin syndrome occurred within 6 months in Finland in subjects who had ingested overdosages of moclobemide-citalopram or moclobemide- clomipramine combinations. Three of these subjects had ingested only a moderate mixed overdose. These cases indicated the substantial risk caused by the combined ingestion of moclobemide and serotonergic drugs, even after their relatively small overdoses, although moclobemide overdosage alone was known to be relatively harmless.

Activated charcoal as gastric decontaminator in acute drug overdosages.
Neuvonen and his groups have shown in experimental and clinical studies in humans, that activated charcoal, when given in adequate doses and early enough, can substantially reduce gastrointestinal absorption of many drugs, also after ingestion of their high toxic doses. The group has characterized, e.g., the effect of charcoal dose, effect of lag time in its administration, and effect of gastric content on the antidotal effect of orally administered charcoal. In addition, the group has discovered that, given in multiple doses, activated charcoal can accelerate elimination of certain drugs by increasing their excretion into gastrointestinal tract. These, about 40 studies on activated charcoal, performed from the 1980 on, have led to significant changes in treatment of acute intoxications. Today, activated charcoal has replaced, in many cases, Ipecac and gastric lavage as gastrointestinal decontaminant (reviews: Neuvonen,1982; Neuvonen & Olkkola, 1988).

download complete CV

[/wm_item]
[wm_item title=”Publications”]

Original Publications

  1. 1967
  2. Torsti P, Neuvonen P: Effect of diuretics on lipolysis in the rat. Ann Med Exp Biol Fenn 1967:45:403-406.
  3. Torsti P, Neuvonen P: Comparison of the lipolytic effects of theophylline and its 7-hydroxypropyl derivatives. Ann Med Exp Biol Fenn 1967:45:407-8
  4. 1968
  5. Vapaatalo HL, Idänpään-Heikkilä JE, Neuvonen PJ: On the accumulation of 35S-chlorpromazine in the adrenal gland. Psychopharmacologia 1968:13:14-21
  6. Idänpään-Heikkilä JE, Vapaatalo HI, Neuvonen PJ: Effect of N-hydroxyethylpromethazine (AprobitR) on the distribution of 35S-chlorpromazine studied by autoradiography in cats and mice. Psychopharmacologia 1968:13:1-13
  7. Neuvonen PJ, Idänpään-Heikkilä JE, Vapaatalo HI: Effect of N-hydroxy-ethylpromethazine (AprobitR) on the tissue distribution and excretion of 35S-chlorpromazine in cats. Eur J Pharmacol 1968:2:320-322
  8. Neuvonen PJ, Torsti P: Influences of quinidine and mepyramine on adrenaline-induced lipolysis. Ann Med Exp Biol Fenn 1968:46:63-65
  9. Torsti P, Vapaatalo HI, Neuvonen P: Effects of hydrochlorothiazide, furosemide and ethacrynic acid on tissue noradrenaline. Ann Med Exp Biol Fenn 1968:46:57-59
  10. Torsti P, Vapaatalo HI, Neuvonen P: Influence of reserpine, quanethidine and hydrochlorothiazide on tissue catecholamines and metabolism in exercised rats. Ann Med Exp Biol Fenn 1968:46:53-56
  11. 1969
  12. Neuvonen PJ, Vapaatalo HI: Eri furosemidivalmisteiden diureettisen tehon vertailu (Comparison of the diuretic effect of various furosemide products). Suomen Lääkärilehti (Finnish Medical Journal) 1969:24:1942-1946
  13. Vapaatalo HI, Idänpään-Heikkilä JE, Neuvonen PJ, Paasonen MK: Effects of prolonged chlorpromazine treatment on the rat intestine. Acta Pharmacol Toxicol: 1969:27:262-268
  14. Neuvonen PJ, Vapaatalo HI, Torsti P: Tissue catecholamines, blood glucose and plasma free fatty acids after combined treatment with reserpine and diuretics. Eur J Pharmacol 1969:7:180-185
  15. Torsti P, Neuvonen PJ, Vapaatalo HI, Idänpään-Heikkilä JE: Circulatory and diuretic effects of hydrochlorothiazide and reserpine in man. Ann Clin Res 1969:1:126-130
  16. 1970
  17. Airaksinen MM, Neuvonen PJ, Jaakonmäki I: Distribution and fate of 3H-oxypertine in rats. Biochem Pharmacol 1970:19:2181-2191
  18. Neuvonen PJ, Gothoni G, Hackman R, af Björksten K: Interference of iron with the absorption of tetracyclines in man. Br Med J: 1970:4:532-534
  19. 1971
  20. Gothoni G, Neuvonen PJ, af Björksten K, Hackman R: Tetrasykliinien imeytymiseen vaikuttavista tekijöistä (On the factors influencing the absorption of tetracyclines). Suomen Lääkäririlehti (Finnish Medical Journal) 1971:26:259-263
  21. Neuvonen PJ: Pressor responses in diuretic-treated normotensive rats. Ann Med Exp Biol Fenn 1971:49:101-108
  22. Neuvonen PJ: Influence of diuretics and diazoxide on ions and vascular reactivity in normotensive and spontaneously hypertensive rats. Ann Med Exp Biol Fenn 1971:49:109-119
  23. Neuvonen PJ, Karppanen H: Effects of hydrochlorothiazide, furosemide and ethacrynic acid on pinealectomy-induced hypertension in rats. Ann Med Exp Biol Fenn 1971:49:120-124
  24. Vapaatalo HI, Neuvonen PJ, Tissari A, Mansner R, Paasonen MK: Effect of cigarette smoking on diuresis induced by furosemide. Ann Clin Res 1971:3:159-162
  25. Neuvonen PJ, Vapaatalo H, Westermann E: On the mechanism of some metabolic actions of dopamine. Naunyn-Schmiedebergs Arch Pharmakol 1971:271:325-329
  26. Mattila MJ, Neuvonen PJ, Gothoni G, Hackman CR: Interference of iron preparations and milk with the absorption of tetracyclines. In Excerpta Medica Int Congr Ser No. 254: Toxicological Problems of Drug Combinations: 1971:128-133
  27. 1972
  28. Gothoni G, Neuvonen PJ, Mattila M, Hackman CR: Iron-tetracycline interaction: Effect of time interval between the drugs. Acta Med Scand 1972:191:409-411
  29. Westermann E, Neuvonen PJ, Onken D, Vapaatalo H: Studies on the mechanism of some metabolic effects of oxyfedrine. In Action of Oxyfedrine. Gerlach E, Moser K, eds., FK Schattauer Verlag, Stuttgart – New York. 1972:135-144
  30. 1973
  31. Neuvonen PJ, Westermann E: On the cardiovascular action of dopamine in rats. Naunyn- Schmiedebergs Arch Pharmakol 1973:280:363-371
  32. Hackman R, Pentikäinen P, Neuvonen PJ, Vapaatalo H: Inhibition of the apomorphine gnawing compulsion by amantadine. Experientia 1973:29:1524-5
  33. 1974
  34. Neuvonen PJ, Penttilä O: Interaction between doxycycline and barbiturates. Br Med J 1974:I:535- 536
  35. Neuvonen PJ, Turakka H: Inhibitory effect of various iron salts on the absorption of tetracyclines in man. Eur J Clin Pharmacol 1974:7:357-360
  36. Neuvonen PJ, Penttilä O: Effect of oral ferrous sulphate on the half-life of doxycycline in man. Eur J Clin Pharmacol 1974:7:361-363
  37. Penttilä O, Neuvonen PJ, Aho K, Lehtovaara R: Interaction between doxycycline and some antiepileptic drugs. Br Med J 1974:I:470-472
  38. Vapaatalo H, Hackman CR, Anttila P, Vainionpää V, Neuvonen PJ: Effects of 6-hydroxydopamine on spontaneously hypertensive rats. Naunyn-Schmiedebergs Arch Pharmakol 1974:284:1-13
  39. Karppanen HO, Neuvonen PJ, Bieck PR, Westermann E: Effect of histamine, pentagastrin and theophylline on the production of cyclic AMP in isolated gastric tissue of the guinea pig. Naunyn- Schmiedebergs Arch Pharmakol 1974:284:15-23
  40. Neuvonen PJ, Westermann E: Studies on some metabolic effects of DOPA and dopamine in rat. Naunyn-Schmiedebergs Arch Pharmakol 1974:284:115-131
  41. Vapaatalo H, Neuvonen PJ, Torsti P: Effects of combined treatment with hydrochlorothiazide and reserpine or guanethidine on catecholamine content in the heart, kidney and arterial wall in the rats. Proc First Congr Hungarian Pharmacol Soc, Budapest, 1974:243-249
  42. 1975
  43. Neuvonen PJ, Pentikäinen P, Gothoni G: Inhibition of iron absorption by tetracycline. Br J Clin Pharmacol 1975:2:94-6
  44. Vapaatalo H, Onken D, Neuvonen PJ, Westermann E: Stereospecificity in central and circulatory effects of phenylisopropyl-adenosine (PIA). Arzneimittel-Forschung (Drug Res) 1975:25:407-410
  45. Vapaatalo H, Neuvonen PJ, Bieck P, Westermann E: Actions of various methylxanthines and papaverine on the synthesis of corticosterone in vitro. Arzneimittel-Forschung (Drug Res) 1975:25:1265-1269
  46. Pentikäinen PJ, Neuvonen PJ, Elfving SM: Bioavailability of four brands of phenytoin tablets. Eur J Clin Pharmacol 1975:9:213-218
  47. Neuvonen PJ, Penttilä O, Lehtovaara R, Aho K: Effect of antiepileptic drugs on the elimination of various tetracycline derivatives. Eur J Clin Pharmacol 1975:9:147-154
  48. Penttilä O, Hurme H, Neuvonen PJ: Effect of zinc sulphate on the absorption of tetracycline and doxycycline in man. Eur J Clin Pharmacol 1975:9:131-134
  49. 1976
  50. Neuvonen PJ, Penttilä O, Roos M, Tirkkonen J: Effect of long-term alcohol consumption on the half- life of tetracycline and doxycycline in man. Int J Clin Pharmacol Biopharm 1976:14:303-307
  51. Elonen E, Neuvonen PJ, Vapaatalo H: Effects of oral glucose, fructose and/or bicarbonate on exercised-induced alterations in some biochemical parameters. J Sports Med Physical Fitness 1976:16:277-284
  52. 1977
  53. Neuvonen PJ, Elonen E, Pentikäinen PJ: Comparative effect of food on absorption of ampicillin and pivampicillin. J Int Med Res 1977:5:71-76
  54. Pentikäinen PJ, Penttilä A, Neuvonen PJ, Gothoni G: Fate of 14C-bumetanide in man. Br J Clin Pharmacol 1977:4:39-44
  55. Neuvonen PJ, Pentikäinen PJ, Elfving SM: Factors affecting the bioavailability of phenytoin. Int J Clin Pharmacol Biopharm 1977:15:84-89
  56. Ylitalo P, Hinkka H, Neuvonen PJ: Effect of exercise on the serum level and urinary excretion of tetracycline, doxycycline and sulphamethizole. Eur J Clin Pharmacol 1977:12:367-373
  57. 1978
  58. Jounela AJ, Pentikäinen PJ, Neuvonen PJ: Antihypertensive effect of trimepranol, a new beta blocking agent. Int J Clin Pharmacol Biopharm 1978:16:183-188
  59. Pentikäinen PJ, Neuvonen PJ, Penttilä A: Assessment of beta-blocking activity of trimepranol in man. Int J Clin Pharmacol Biopharm 1978:16:279-284
  60. Neuvonen PJ, Pentikäinen PJ, Jounela AJ: Effect of diuretic, -adrenoceptor blocking agent and their combination on elevated blood pressure and serum potassium: A cross-over study. Br J Clin Pharmacol 1978:6:363-367
  61. Neuvonen PJ, Elfving SM, Elonen E: Reduction of absorption of digoxin, phenytoin and aspirin by activated charcoal in man. Eur J Clin Pharmacol 1978:13:213-218
  62. Pentikäinen PJ, Neuvonen PJ, Tarpila S, Syvälahti E: Effect of cirrhosis of the liver on the pharmacokinetics of chlormethiazole. Br Med J 1978:2:861-
  63. 1979
  64. Elonen E, Neuvonen PJ, Halmekoski J, Mattila MJ: Acute dapsone intoxication: A case with prolonged symptoms. Clin Toxicol 1979:14:79-85
  65. Neuvonen PJ, Vilska J, Keränen A: Severe poisoning in a child caused by a small dose of clonidine. Clin Toxicol 1979:14:369-374
  66. Neuvonen PJ, Bardy A, Lehtovaara R: Effect of increased bioavailability of phenytoin tablets on serum phenytoin concentration in epileptic out-patients. Br J Clin Pharmacol 1979:8:37-41
  67. Neuvonen PJ, Lehtovaara R, Bardy A, Elomaa E: Antipyretic analgesics in patients on antiepileptic drug therapy. Eur J Clin Pharmacol 1979:15:263-8
  68. Elonen E, Neuvonen PJ, Tarssanen L, Kala R: Sotalol intoxication with prolonged Q-T interval and severe tachyarrhythmias. Br Med J 1979:1:1184-1186
  69. Neuvonen PJ, Elonen E, Tarssanen L: Sotalol intoxication, two patients with concentration-effect relationships. Acta Pharmacol Toxicol 1979:45:52-57
  70. Pentikäinen PJ, Neuvonen PJ, Penttilä A: Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 1979:16:195-202
  71. 1980
  72. Pentikäinen PJ, Neuvonen PJ, Jostell KG: Pharmacokinetics of chlormethiazole in healthy volunteers and patients with cirrhosis of the liver. Eur J Clin Pharmacol 1980:17:275-284
  73. Neuvonen PJ, Elonen E: Phenobarbitone elimination rate after oral charcoal. Br Med J 1980:1:762
  74. Neuvonen PJ, Elonen E: Effect of activated charcoal on absorption and elimination of phenobarbitone, carbamazepine and phenylbutazone in man. Eur J Clin Pharmacol 1980:17:51-57
  75. Neuvonen PJ, Elonen E, Mattila MJ: Oral activated charcoal and dapsone elimination. Clin Pharmacol Ther 1980:27:823-827
  76. Pentikäinen PJ, Neuvonen PJ, Kekki M, Penttilä A: Pharmacokinetics of intravenously administered bumetanide in man. J Pharmacokin Biopharm 1980:8:219-228
  77. Neuvonen PJ, Lehtovaara R, Bardy A: Effect of some gastrointestinal factors on serum phenytoin concentration. In Antiepileptic Therapy: Advances in Drug Monitoring, eds. Johannessen et al., Raven Press, New York, 1980:149-156
  78. Lehtovaara R, Bardy A, Neuvonen PJ: Effect of dose modification on the serum concentration of phenytoin and carbamazepine. In Antiepileptic Therapy: Advances in Drug Monitoring, eds. Johannessen et al., Raven Press, New York, 1980:287-290
  79. 1981
  80. Neuvonen PJ, Elonen E, Vuorenmaa T, Laakso M: Prolonged Q-T interval and severe tachyarrhythmias, common features of sotalol intoxication. Eur J Clin Pharmacol 1981:20:85-89
  81. Laakso M, Pentikäinen PJ, Pyörälä K, Neuvonen PJ: Prolongation of the Q-T interval caused by sotalol – possible association with ventricular tachyarrhythmias. Eur Heart J 1981:2:353-358
  82. Kaukola S, Manninen V, Neuvonen PJ, Mälkönen M, Ehnholm C: Effect of phenytoin on serum lipoproteins in middle-aged men. J Cardiovasc Pharmacol 1981:3:207-214
  83. Neuvonen PJ, Tokola RA, Kaste M: Cimetidine-phenytoin interaction: Effect on serum phenytoin concentration and antipyrine test. Eur J Clin Pharmacol 1981:21:215-220
  84. Neuvonen PJ, Pentikäinen PJ, Jostell KG, Syvälahti E: Effect of ethanol on the pharmacokinetics of chlormethiazole in humans. Int J Clin Pharmacol Ther Toxicol 1981:19:552-560
  85. Rosenberg PH, Oikkonen M, Neuvonen PJ, Leander P: Metabolic ability and enflurane defluorination in surgical patients. Acta Anaesth Scand 1981:25:246-253
  86. Pentikäinen PJ, Neuvonen PJ, Backman C: Human pharmacokinetics of tolfenamic acid, a new anti- inflammatory agent. Eur J Clin Pharmacol 1981:19:359-365
  87. 1982
  88. Neuvonen PJ, Elonen E, Tanskanen A, Tuomilehto J: Sotalol prolongation of the Q-T interval in hypertensive patients. Clin Pharmacol Ther 1982:32:25-32
  89. Tokola RA, Anttila V-J, Neuvonen PJ: The effect metoclopramide on the absorption of tolfenamic acid. Int J Clin Pharmacol Ther Toxicol 1982:20:465-468
  90. Linden I-B, Neuvonen PJ, Vapaatalo H: Effects of 3,4-dihydroxy-phenylpyruvic acid and its triacetylated derivative on DOPA decarboxylase. Acta Pharmacol Toxicol 1982:51:266-269
  91. Pentikäinen PJ, Penttilä A, Neuvonen PJ, Khalifah RG, Hignite CE: Human metabolism of tolfenamic acid. I. Isolation, preliminary characterization and pharmacokinetics of tolfenamic acid and its metabolites. Eur J Drug Metab Pharmacokin 1982:7:259-267
  92. Khalifah RG, Hignite CE, Pentikäinen PJ, Penttilä A, Neuvonen PJ: Human metabolism of tolfenamic acid. II. Structure of metabolites and C-13 NMR assigments of fenamates. Eur J Drug Metab Pharmacokin 1982:7:269-276
  93. 1983
  94. Kärkkäinen S, Vapaatalo HI, Neuvonen PJ: Urine pH is important for chlorpropamide elimination. Diabetes Care 1983:6:313
  95. Pentikäinen PJ, Neuvonen PJ, Penttilä A: Pharmacokinetics and pharmacodynamics of glipizide in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1983:21:98-107
  96. Neuvonen PJ, Kannisto H, Hirvisalo E-L: Effect of activated charcoal on absorption of tolbutamide and valproate in man. Eur J Clin Pharmacol 1983:24:243-246
  97. Neuvonen PJ, Kärkkäinen S: Effects of oral charcoal, sodium bicarbonate and ammonium chloride on chlorpropamide kinetics. Clin Pharmacol Ther 1983:33:386-393
  98. Neuvonen PJ, Vartiainen M, Tokola O: Comparison of activated charcoal and ipecac syrup in prevention of drug absorption. Eur J Clin Pharmacol 1983:24:557-562
  99. Neuvonen PJ, Elonen E, Haapanen EJ: Acute dapsone intoxication: Clinical findings and effect of oral charcoal and haemodialysis on dapsone elimination. Acta Med Scand 1983:214:215-220
  100. Kaste M, Muuronen A, Nikkilä EA, Neuvonen PJ: Increase of low serum concentrations of high- density lipoprotein (HDL) cholesterol in TIA-patients treated with phenytoin. Stroke 1983:14:525- 530
  101. Nilsson E, Meretoja OA, Neuvonen PJ: Hemodynamic responses to physostigmine in patients with drug overdosage. Anesth Analg 1983:62:885-888
  102. 1984
  103. Neuvonen PJ, Olkkola KT, Alanen T: Effect of ethanol and pH on the adsorption of drugs to activated charcoal: Studies in vitro and in man. Acta Pharmacol Toxicol 1984:54:1-7
  104. Kannisto H, Neuvonen PJ: Adsorption of sulphonylureas to activated charcoal in vitro. J Pharm Sci 1984:73:253-256
  105. Elonen E, Neuvonen PJ: Mixed dextropropoxyphene poisoning: Concentration-effect relationships and effect of naloxone. Int J Clin Pharmacol Ther Toxicol 1984:22:16-19
  106. Tokola RA, Kangasniemi P, Neuvonen PJ, Tokola O: Tolfenamic acid, metoclopramide, caffeine and their combinations in the treatment of migraine attacks. Cephalalgia 1984:4:253-263
  107. Neuvonen PJ, Kannisto H, Lankinen S: Capacity of two forms of charcoal to adsorb nefopam in vitro and to reduce its toxicity in vivo. J Toxicol – Clinical Toxicol 1983:21:333-342
  108. Tokola RA, Neuvonen PJ: Effects of migraine attrack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol 1984:17:67-75
  109. Oikkonen M, Rosenberg PH, Neuvonen PJ: Hepatic metabolic ability during anaestesia. Evaluation of antipyrine half-lives and their relation to enflurane metabolism. Anaesthesia 1984:39:660-665
  110. Neuvonen PJ, Olkkola KT: Effect of dose of charcoal on the absorption of disopyramide, indomethacin and trimethoprim by man. Eur J Clin Pharmacol 1984:26:761-767
  111. Kärkkäinen S, Neuvonen PJ: Effect of oral charcoal and urine pH on sotalol pharmacokinetics. Int J Clin Pharmacol Ther Toxicol 1984:22:441-6
  112. Olkkola KT, Neuvonen PJ: Do gastric contents modify antidotal efficacy of oral activated charcoal. Br J Clin Pharmacol 1984:18:663-669
  113. Neuvonen PJ, Olkkola KT: Activated charcoal and ipecac syrup in prevention of cimetidine and pindolol absorption in man after administration metoclopramide as an antiemetic agent. J Toxicol – Clin Toxicol 1984:22:103-114
  114. Olkkola KT, Neuvonen PJ: Effect of gastric pH on antidotal efficacy of activated charcoal in man. Int J Clin Pharmacol Ther Toxicol 1984:22:565-9
  115. Tokola RA, Neuvonen PJ: Effect of migraine attacks on paracetamol absorption. Brit J Clin Pharmacol 1984:18:867-871
  116. 1985
  117. Kärkkäinen S, Neuvonen PJ: Effect of oral charcoal and urine pH on dextropropoxyphene pharmacokinetics. Int J Clin Pharmacol Ther Toxicol 1985:23:219-225
  118. Pentikäinen PJ, Pasternack A, Lampainen E, Neuvonen PJ, Penttilä A: Bumetanide kinetics in renal failure. Clin Pharmacol Ther 1985:37:582-588
  119. Neuvonen PJ: Bioavailability and central side effects of different brands of carbamazepine tablets. Int J Clin Pharmacol Ther Toxicol 1985:23:226-232
  120. Neuvonen PJ, Jaakkola A, Tötterman J, Penttilä O: Clinically significant sucralfate-warfarin interaction is not likely. Brit J Clin Pharmacol 1985:20:178-180
  121. Neuvonen PJ, Tokola O, Toivonen M-L, Simell O: Methionine in paracetamol tablets, a tool to reduce paracetamol toxicity. Int J Clin Pharmacol Ther Toxicol 1985:23:497-500
  122. 1986
  123. Penttilä O, Neuvonen PJ, Vuori E, Himberg J-J, Siltanen P, Järvinen A, Merikallio E: Auricular myocardial cation concentrations in certain heart diseases in man. Trace Elements in Medicine. 1986:3:47-51
  124. Tiula E, Neuvonen PJ: Effect of total drug concentration on the free fraction in uremic sera. Therap Drug Monit 1986:8:27-31
  125. Kärkkäinen S, Neuvonen PJ: Pharmacokinetics of amitriptyline influenced by oral charcoal and urine pH. Int J Clin Pharmacol Ther Toxicol 1986:24:326-332
  126. Neuvonen PJ, Olkkola KT: Effect of purgatives on antidotal efficacy of oral activated charcoal. Human Toxicol 1986:5:255-263
  127. Koivisto K, Sivenius J, Keränen T, Partanen J, Riekkinen P, Gothoni G, Tokola O, Neuvonen PJ: Clinical trial with an experimental taurine derivative, taltrimide, in epileptic patients. Epilepsia 1986:27:87-90
  128. Kuusisto P, Vapaatalo H, Manninen V, Huttunen JK, Neuvonen PJ: Effect of activated charcoal on hypercholesterolaemia. The Lancet 1986:II:366-367
  129. 1987
  130. Neuvonen PJ, Kärkkäinen S, Lehtovaara R: Pharmacokinetics of chlorpropamide in epileptic patients: Effects of enzyme induction and urine pH on chlorpropamide elimination. Eur J Clin Pharmacol 1987:32:297-301
  131. Tiula E, Tallgren LG, Neuvonen PJ: Serum protein binding of phenytoin, diazepam and propranolol in chronic renal diseases. Int J Clin Pharmacol Ther Toxicol 1987:25:545-552
  132. Tiula E, Haapanen EJ, Neuvonen PJ: Factors affecting serum protein binding of phenytoin, diazepam and propranolol in acute renal diseases. Int J Clin Pharmacol Ther Toxicol 1987:25:469-475
  133. Keränen T, Partanen VSJ, Koivisto K, Tokola O, Neuvonen PJ, Riekkinen PJ: Effects of taltrimide, an experimental taurine derivative, on photoconvulsive response in epileptic patients. Epilepsia 1987:28:133-7
  134. Airaksinen EM, Koivisto K, Keränen T, Pitkänen A, Riekkinen PJ, Oja SS, Marnela K-M, Partanen JV, Tokola O, Gothoni G, Neuvonen PJ, Airaksinen MM: Biochemical and clinical studies on epileptic patients during two phase I trials with the novel anticolvulsant taltrimide. Epilepsy Res 1987:1:308-311
  135. Neuvonen PJ, Tokola O: Bioavailability of rectally administered carbamazepine mixture. Brit J Clin Pharmacol 1987:24:839-841
  136. Neuvonen PJ, Santavuori P, Sainio K, Uotila K: A pilot study with taltrimide in intractable epilepsy in children. Proc Meeting Eur Feder Child Neurol Soc. Hyvinkää, Finland, 15-18.6. 1987.
  137. Santavuori P, Riikonen R, Meretoja O, Sainio K, Neuvonen PJ, Tokola RA: Effect of long barbiturate anaesthesia on intractable epilepsy in children. Proc Meeting Eur Feder Child Neurol Soc. Hyvinkää, Finland, 15-18.6. 1987.
  138. Riikonen R, Santavuori P, Meretoja O, Sainio K, Neuvonen PJ, Tokola RA: Effect of short barbiturate anaesthesia on infantile spasms. Proc Meeting Eur Feder Child Neurol Soc. Hyvinkää, Finland, 15-18.6. 1987.
  139. 1988
  140. Meretoja OA, Wirtavuori K, Neuvonen PJ: Age-dependence of the dose-response curve of vecuronium in pediatric patients during balanced anesthesia. Anesth Analg 1988:67:21-26
  141. Neuvonen PJ, Kivistö K, Hirvisalo EL: Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide. Brit J Clin Pharmacol 1988:25:229-233
  142. Neuvonen PJ, Kivistö KT: Effect of magnesium hydroxide on the absorption of tolfenamic and mefenamic acids. Eur J Clin Pharmacol, 1988:35:495-501
  143. Riikonen R, Santavuori, P, Meretoja O, Sainio K, Neuvonen PJ, Tokola RA: Can barbiturate anaesthesia cure infantile spasms? Brain Dev 1988:10:300-304
  144. 1989
  145. Hynynen M, Olkkola KT, Näveri E, Palojoki R, Neuvonen PJ & Heinonen J: Thiopentone pharmacokinetics during cardiopulmonary bypass with a nonpulsatile or pulsatile flow. Acta Anaesthesiol Scand 1989:33:554-560
  146. Neuvonen PJ, Kivistö K: Activated charcoal should replace the resins in the treatment of digoxin intoxication. Arch Int Med 1989:149:2603
  147. Neuvonen PJ, Kuusisto P, Manninen V, Vapaatalo H, Miettinen TA: The mechanism of the hypocholesterolaemic effect of activated charcoal. Eur J Clin Investig 1989:19:251-254
  148. Neuvonen PJ, Kuusisto P, Vapaatalo H, Manninen V: Activated charcoal in the treatment of hypercholesterolaemia: dose-response relationships and comparison with cholestyramine. Eur J Clin Pharmacol 1989:37:225-230
  149. Taivainen T, Hiller A, Rosenberg PH, Neuvonen P: The effect of continuous intravenous indomethacin infusion on bleeding time and postoperative pain in patients undergoing emergency surgery of the lower extremities. Acta Anaesthesiol Scand 1989:33:58-60
  150. The Scandinavian Oxcarbazepine Study Group (Neuvonen Pertti incluced): A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989:3:70-76
  151. 1990
  152. Bardy AH, Hiilesmaa VK, Teramo K, Neuvonen PJ: Protein binding of antiepileptic drugs during pregnancy, labor, and puerperium. Therap Drug Monit 1990:12:40-46
  153. Hirvisalo E-L, Kivistö KT, Neuvonen PJ: Therapeutic cyclosporine monitoring: comparison of radioimmunoassay and high-performance liquid chromatography methods in organ transplant recipients. Therap Drug Monit 1990:12:353-358
  154. Iivanainen M, Waltimo O, Tokola O, Parantainen J, Tamminen M, Allonen H, Neuvonen PJ: A controlled study with taltrimide and sodium valproate: valproate effective in partial epilepsy. Acta Neurol Scand 1990:82:121-125
  155. Kivistö KT, Neuvonen PJ: Effect of activated charcoal on frusemide induced diuresis: a human class experiment for medical students. Brit J clin Pharmacol 1990:30:496-498
  156. Kivistö KT, Neuvonen PJ: The effect of cholestyramine and activated charcoal on glipizide absorption. Brit J clin Pharmacol 1990:30:733-736
  157. 1991
  158. Kivistö KT, Neuvonen PJ: Enhancement of absorption and effect of glipizide by magnesium hydroxide. Clin Pharmacol Ther 1991:49:39-43
  159. Kivistö KT, Neuvonen PJ: Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide. Eur J Clin Pharmacol 1991:40:383-386
  160. Neuvonen PJ: Effect of magnesium hydroxide on the absorption of ibuprofen, ketoprofen and diclofenac. Brit J clin Pharmacol 1991:31:263-266
  161. Neuvonen PJ, Kivistö K: The effects of magnesium hydroxide on the absorption and efficacy of two glibenclamide preparations. Brit J clin Pharmacol 1991:32:215-220
  162. Tigerstedt I, Tammisto T, Neuvonen PJ: The efficacy of intravenous indomethacin in prevention of postoperative pain. Acta Anaestiol Scand 1991:35:535-540
  163. Kivistö KT, Neuvonen PJ: Effects of activated charcoal on the absorption of amiodarone. Human and Experimental Toxicol 1991:10:327-329
  164. Neuvonen PJ, Roivas L, Laine K, Sundholm: The bioavailability of sustained release nicotinic acid formulations. Brit J clin Pharmacol 1991:32:473-476
  165. Neuvonen PJ, Kivistö KT, Lehto P: Interference of dairy products with the absorption of ciprofloxacin. Clin Pharmacol Ther 1991:50:498-502
  166. Peltola H, Renkonen O, Neuvonen PJ: Single-dose pharmacokinetics of oral ciprofloxacin in children. Eur J Clin Microbiol Infect Dis. 1991, Proceedings 3rd Int Symposium on New Quinolones, (E. Rubinstein, Ed.), pp. 424-425.
  167. 1992
  168. Neuvonen PJ, Kivistö K, Laine K, Pyykkö K: Prevention of chloroquine absorption by activated charcoal. Human and Experimental Toxicol 1992:11:117-120.
  169. Kivistö KT, Neuvonen PJ: Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide. Eur J Clin Pharmacol 1992:42:675-80.
  170. Kivistö KT, Ojala-Karlsson P, Neuvonen PJ: Inhibition of norfloxacin absorption by dairy products. Antimicrobial Agents and Chemother 1992:36:489-91.
  171. Neuvonen PJ, Kivistö KT: Milk and yoghurt do not impair the absorption of ofloxacin. Brit J clin Pharmacol 1992:33:346-348.
  172. Alfthan G, Pesonen E, Neuvonen PJ, Hirvonen J, Karkola K, Laaksonen H, Räsänen L, Åkerblom HK: Relationships between myocardial macrominerals and trace elements and luminal narrowing of coronary arteries in Finnish children. J Trace Elem Electrolytes Health Dis 1992:6:45-49.
  173. Peltola H, Väärälä M, Renkonen O-V, Neuvonen PJ: Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children. Antimicrobial Agents and Chemother 1992:36:1086-90.
  174. Roivas L, Neuvonen PJ: Reversible adsorption of nicotinic acid onto charcoal in vitro. J Pharm Sci 1992: 81:917-19.
  175. 1993
  176. Kuitunen A, Hynynen M, Salmenperä M, Rasi V, Järvinen A, Scheinin M, Neuvonen PJ, Fyhrquist F: Anaesthesia affects plasma concentrations of vasopressin, von Willebrand factor and coagulation factor VIII in cardiac surgical patients. Br J Anaesth 1993:70:173-180.
  177. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg J-J, Neuvonen PJ: A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993:53:298-305.
  178. Laine K, Kivistö KT, Neuvonen PJ. Failure of oral activated charcoal to accelerate the elimination of chloroquine and amiodarone. Human and Experimental Toxicol 1992:11:491-494.
  179. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen PJ: Torsades de pointes after terfenadine- itraconazole interaction. Br Med J 1993:306:186
  180. Kivistö K, Lehto P, Neuvonen PJ: The effects of different doses of sodium bicarbonate on the absorption and activity of non-micronized glibenclamide. Int J Clin Pharmacol Ther Toxicol 1993:31:236-240.
  181. Inberg P, Tarkkila P, Neuvonen PJ, Vilkki S: Regional anesthesia for microvascular surgery – A combination of brachial plexus, spinal and epidural blocks. Regional Anesthesia 1993:18:98-102.
  182. Lindgren L, Yli-Hankala A, Randell T, Kirvelä M, Scheinin M, Neuvonen PJ: Haemodynamic and catecholamine responses to induction of anaesthesia and to tracheal intubation: comparison between propofol or thiopentone. Br J Anaesth 1993:70:173-180
  183. Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E: Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet 1993:342:1419
  184. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen PJ: Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993:45:191-193.
  185. 1994
  186. Kivistö KT, Kallio A, Neuvonen PJ: Pharmacokinetics and pharmacodynamics of transdermal dexmedetomidine. Eur J Clin Pharmacol 1994:46:345-349
  187. Lehto P, Kivistö K, Neuvonen PJ: Effect of ferrous sulphate on the absorption of norfloxacin, ciprofloxacin, and ofloxacin. Br J Clin Pharmacol 1994:37:82-85.
  188. Laine K, Kivistö KT, Neuvonen PJ: The effect of activated charcoal on the absorption and elimination of astemizole. Human and Experimental Toxicol 1994:13:502-6.
  189. Roivas L, Neuvonen PJ: Drug adsorption onto activated charcoal as a means of formulation. Methods and Findings Exp Clin Pharmacol 1994:16:367-72.
  190. Roivas L, Kaila T, Ojala-Karlsson P, Neuvonen PJ: The bioavailability of two beta-blockers preadsorbed onto charcoal. Methods and Findings Exp Clin Pharmacol 1994:16:367-72.
  191. Roivas L, Kivistö KT, Neuvonen PJ: Desorption of furosemide from charcoal in vitro and in man. Int J Clin Pharmac Ther Tox 1994:32:198-203.
  192. Aranko K, Luurila H, Backman JT, Neuvonen PJ, Olkkola KT: The effect of erythromycin on the pharmacokinetics and pharmacodynamics of zopiclone. Br J Clin Pharmacol 1994:38:363-367.
  193. Kaila T, Roivas L, Neuvonen PJ: Receptor binding assays in analysing the bioavailability and pharmacodynamic bioequivalence of active drug moieties. A study of metoprolol. Eur J Clin Pharmacol 1994:46;237-242.
  194. Backman JT, Olkkola KT, Aranko K, Himberg J-J, Neuvonen PJ: Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharm 1994:37;221-225.
  195. Hynynen M, Hynninen M, Soini H, Neuvonen PJ, Heinonen J: Plasma concentration and protein binding of alfentanil during high-dose infusion for cardiac surgery. Br J Anaesth 1994:72;571-576.
  196. Luurila H, Olkkola KT, Neuvonen PJ: Erythromycin does not interact with temazepam. Therap Drug Monit 1994:16;548-551.
  197. Olkkola KT, Backman JT, Neuvonen PJ: Midazolam should be avoided in patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharm Ther 1994:55;481-485.
  198. Tohmo H, Karanko M, Korpilahti K, Scheinin M, Viinamäki O, Neuvonen P: Enalaprilat in acute intractable heart failure after myocardial infarction: A prospective, consecutive sample, before-after trial. Critical Care Medicine 1994:22;965-973.
  199. Varhe A, Olkkola KT, Neuvonen PJ: Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994:56:601-7.
  200. Luutonen S, Antila K, Neuvonen PJ, Räihä I, Rajala T, Sourander L: Spectral analysis of heart rate variability in evaluation of sympathetic function in elderly subjects. Age and Ageing 1994:23:473-7.
  201. 1995
  202. Neuvonen PJ, Suhonen R: Itraconazole interacts with felodipine. J Am Acad Dermatol 1995:33:134- 5.
  203. Luutonen S, Neuvonen PJ, Ruskoaho H, Räihä I, Rajala T, Antila K, Sourander L: The role of potassium in postural hypotension: electrolytes and neurohumoral factors in elderly hypertensive patients using diuretics. J Internal Medicin 1995:237:375-380.
  204. Inberg P, Kassila M, Vilkki SK, Tarkkila P, Neuvonen P: Anesthesia for microvascular surgery in children. A combination of general anaesthesia and axillary plexus block. Acta Anaesthesiol Scand 1995:39:518-522.
  205. Backman JT, Olkkola KT, Neuvonen PJ: Azithromycin does not increase plasma concentrations of oral midazolam. Int J Clin Pharmacol Ther 1995:33:356-359.
  206. Ahonen J, Olkkola KT, Neuvonen PJ: Effect of two antimycotics, itraconazole and terbinafine, on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol 1995: 40:270-272.
  207. Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ: Effect of grapefruit juice on the bioavailability of triazolam in man. Clin Pharmacol Ther 1995:58:127-131.
  208. Luurila H, Olkkola KT, Neuvonen PJ: Interaction between erythromycin and nitrazepam in healthy volunteers. Pharmacology and Toxicology 1995:76:255-258.
  209. Kalso E, Tasmuth T, Neuvonen PJ: Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain 1995:64:293-302.
  210. 1996
  211. Olkkola KT, Ahonen J, Neuvonen PJ: The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 1996:82:511-516
  212. Ahonen J, Olkkola KT, Neuvonen PJ: Lack of effect of antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam. TDM 1996:18:124-7.
  213. Backman JT, Olkkola KT, Neuvonen PJ: Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996:59:7-13
  214. Ahonen J, Olkkola KT, Neuvonen PJ: The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam. Fundam Clin Pharmacol 1996:10:314-8.
  215. Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ: Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 1996:37:253-7
  216. Lukkari E, Castrén-Kortekangas P, Juhakoski A, Löyttyniemi E, Aranko K, Neuvonen PJ: Effect of food on the bioavailability of oxybutynin from a controlled release tablet. Eur J Clin Pharm 1996;50:221-3
  217. Luurila H, Olkkola KT, Neuvonen PJ: Interaction between erythromycin and the benzodiazepines diazepam and flunitrazepam. Pharmacology and Toxicology 1996:78:117-22.
  218. Varhe A, Olkkola KT, Neuvonen PJ: Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br J Clin Pharmacol 1996:41:319-323
  219. Varhe A, Olkkola KT, Neuvonen PJ: Diltiazem enhances the effects of triazolam by inhibiting its metabolism. Clin Pharmacol Ther 1996:59:369-95
  220. Neuvonen PJ, Jalava M: Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996:60:54-61.
  221. Neuvonen PJ, Varhe A, Olkkola KT: The effect of ingestion time interval on the interaction between itraconazole and triazolam. Clin Pharmacol Ther 1996:60:326-31.
  222. Varhe A, Olkkola KT, Neuvonen PJ: Effect of fluconazole dose on the extent of fluconazole- triazolam interaction. Br J clin Pharmacol 1996:42:465-470
  223. Partanen J, Jalava M, Neuvonen PJ: Itraconazole increases serum digoxin concentration. Pharmacology and Toxicology 1996:79:274-276
  224. Ahonen J, Olkkola KT, Salmenperä M, Hynynen M, Neuvonen PJ: Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting. Anesthesiology 1996:85:1246-52.
  225. Lehto P, Laine K, Kivistö KT, Neuvonen PJ: The effect of pH on the in-vitro dissolution of three second-generation sulfonylurea preparations – Mechanism for antacid-sulfonylurea interaction. J Pharm Pharmacol 1996:48:899-901
  226. Laine K, Kivistö KT, Pelttari S, Neuvonen PJ: The effect of activated charcoal on the absorption of fluoxetine, with special reference to delayed charcoal administration. Pharmacology and Toxicology 1996:79:270-273
  227. Jalava K-M, Olkkola KT, Neuvonen PJ: Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. Eur J Clin Pharmacol 1996:51:331-4.
  228. 1997
  229. Villikka K, Kivistö KT, Backman J, Olkkola KT, Neuvonen PJ: Triazolam is ineffective in patients taking rifampin. Clin Pharmacol Ther 1997:61:8-14
  230. Kivistö KT, Neuvonen PJ, Tarssanen L: Pharmacokinetics of verapamil in overdose. Human & Experimental Toxicology 1997:16:35-7
  231. Laine K, Kivistö KT, Laakso I, Neuvonen PJ: Prevention of amlodipine absorption by activated charcoal; effect of delay in charcoal adminisration. Br J Clin Pharmacol 1997:43:29-33
  232. Laine K, Kivistö KT, Ojala-Karlsson P, Neuvonen PJ: The effect of activated charcoal on the pharmacokinetics of pholcodine, with special reference to delayed charcoal ingestion. Therapeutic Drug Monitoring 1997:19:46-50
  233. Laine K, Kivistö KT, Neuvonen PJ: Effect of delayed administration of activated charcoal on the absorption of conventional and slow-release verapamil. Clinical Toxicology 1997:35:263-8
  234. Ahonen J, Olkkola KT, Neuvonen PJ: Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol 1997;51:415-419
  235. Luomanmäki K, Tiula E, Kivistö K, Neuvonen PJ: Pharmacokinetics of diltiazem in massive overdose. Therapeutic Drug Monitoring 1997:19:240-2.
  236. Villikka K, Kivistö KT, Lamberg TS, Kantola T, Neuvonen PJ: Concentrations and effects of zopiclone are greatly reduced by rifampicin. Br J clin Pharmacol 1997:43:471-4.
  237. Jalava K-M, Olkkola KT, Neuvonen PJ: Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 1997:61:410-15
  238. Valtonen M, Tiula E, Neuvonen PJ: Effect of continuous venovenous haemofiltration and haemodiafiltration on the elimination of fluconazole in patients with acute renal failure. The Journal of Antimicrobial Chemotherapy 1997:40:695-700.
  239. Sarna S, Hoppu K, Neuvonen PJ, Laine J, Holmberg C: Methylprednisolone exposure, rather than the dose, predicts adrenal suppression and growth inhibition in children with liver and renal transplants. J. Clin. Endocrinol & Metab 1997:82:75-77.
  240. Huupponen R, Hirvisalo E-L, Neuvonen PJ: Comparison of cyclophilin binding assay and radioimmunoassay in monitoring of blood cyclosporine. Therapeutic Drug Monitoring 1997:19:446- 449.
  241. Jalava K-M, Partanen J, Neuvonen PJ: Itraconazole decreases the renal clearance of digoxin. Therapeutic Drug Monitoring 1997:19:609-13.
  242. Jalava K-M, Olkkola KT, Neuvonen PJ: Itraconazole increases plasma concentrations of quinidine. Clin Pharmacol Ther 1997:62:510-7.
  243. Kivistö KT, Lamberg T, Kantola T, Neuvonen PJ: Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther 1997:62:348-54.
  244. Lukkari E, Aranko K, Juhakoski A, Hakonen T, Neuvonen PJ: Effect of time interval between food and drug ingestion on the absorption of oxybutynin from a controlled-release tablet. Pharmacol Toxicol 1997: 81:31-34
  245. Lukkari E, Juhakoski A, Neuvonen PJ: Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite. Eur J Clin Pharmacol 1997:52:403-6.
  246. Tohmo H, Karanko M, Klossner J, Scheinin M, Viinamäki O, Neuvonen P, Ruskoaho H: Enalaprilat decreases plasma endothelin and atrial natriuretic peptide levels and preload in patients with left ventricular dysfunction after cardiac surgery. J Cardiothoracic and Vascular Anesthesia 1997:11:585- 90.
  247. Teiriä H, Yli-Hankala A, Neuvonen PJ, Olkkola KT: Effect of cigarette smoking on the pharmacokinetics and pharmacodynamics of thiopentone. Canad J Anaesth 1997:44:1269-74.
  248. Villikka K, Kivistö KT, Luurila H, Neuvonen PJ: Rifampin reduces plasma concentrations and effects of zolpidem. Clin Pharmacol Ther 1997:62:629-34.
  249. 1998
  250. Lukkari E, Hakonen T, Neuvonen PJ: The pharmacokinetics of oxybutynin is unaffected by gender and contraceptive steroids. Eur J Clin Pharmacol 1998:53:351-54
  251. Kaukonen K-M, Olkkola KT, Neuvonen PJ: Fluconazole, but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol 1998:53:445-449
  252. Neuvonen PJ, Kantola T, Kivistö KT: Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998:63:332-41
  253. Kantola T, Kivistö KT, Neuvonen PJ: Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998:63:397-402.
  254. Lamberg TS, Kivistö KT, Neuvonen PJ: Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone. Clin Pharmacol Ther 1998:63:640-5.
  255. Raaska K, Neuvonen PJ: Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole. Eur J Clin Pharmacol 1998:54:167-170.
  256. Kantola T, Kivistö KT, Neuvonen PJ: Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998:64:58-65.
  257. Kantola T, Kivistö KT, Neuvonen PJ: Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998:64:177-82
  258. Backman JT, Kivistö KT, Olkkola KT, Neuvonen PJ: The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 1998:54:53-58.
  259. Luurila H, Kivistö KT, Neuvonen PJ: Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. Eur J Clin Pharmacol 1998:54:163-166.
  260. Kivistö KT, Kantola T, Neuvonen PJ: Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998:46:49-53.
  261. Lamberg TS, Kivistö KT, Neuvonen PJ: Concentrations and effects of buspirone are considerably reduced by rifampicin. Br J Clin Pharmacol 1998:45:381-5
  262. Villikka K, Kivistö KT, Neuvonen PJ: The effect of dexamethasone on the pharmacokinetics of triazolam. Pharmacol Toxicol 1998:81:135-8
  263. Isohanni MH, Neuvonen PJ, Palkama VJ, Olkkola KT: Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine. Eur J Clin Pharmacol 1998:54:561-5
  264. Antila S, Honkanen T, Lehtonen L, Neuvonen PJ: The CYP3A4 inhibitor itraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan. Int J Clin Pharmacol Ther 1998:36:446-9.
  265. Lapatto-Reiniluoto O, Kivistö KT, Pohjola- A prospective study of acute poisonings in Finnish hospital patients. Human and Experimental Toxicology 1998:17:307-311
  266. Palkama VJ, Isohanni MH, Neuvonen PJ, Olkkola KT: The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil. Anesthesia and Analgesia 1998:87:190-4.
  267. Palkama VJ, Neuvonen PJ, Olkkola KT: The CYP3A4 inhibitor itraconazole has no effect on the pharmacokinetics and pharmacodynamics of intravenous fentanyl. Br J Anaesthesia 1998:81:598- 600.
  268. Varis T, Kaukonen K-M, Kivistö KT, Neuvonen PJ: Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Clin Pharmacol Ther 1998:64:363-8
  269. Lamberg TS, Kivistö KT, Laitila J, Mårtensson K, Neuvonen PJ: The effect of fluvoxamine on the
  270. pharmacokinetics and pharmacodynamics of buspirone. Eur J Clin Pharmacol 1998:54:761-6

  271. Lilja JJ, Kivistö KT, Neuvonen PJ: Grapefruit-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998:64:477-83
  272. Kivistö KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ: Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. Clin Pharmacol Ther 1998:64:648-54
  273. Lilja JJ, Kivistö KT, Backman KT, Lamberg TS, Neuvonen PJ: Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther 1998:64:655-60
  274. 1999
  275. Kantola T, Kivistö KT, Neuvonen PJ: Effect of itraconazole on cerivastatin pharmacokinetics. Eur J Clin Pharmacol 1999:54:851-855.
  276. Villikka K, Kivistö KT, Neuvonen PJ: The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. Clin Pharmacol Ther 1999:65:377-81.
  277. Ahonen J, Olkkola KT, Takala A, Neuvonen PJ: Interaction between fluconazole and midazolam in intensive care patients. Acta Anesthesiol Scand 1999:43:509-14.
  278. Kivistö KT, Lamberg T, Neuvonen PJ: Interactions of buspirone with itraconazole and rifampicin: effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine (1-PP) metabolite of buspirone. Pharmacol Toxicol 1999:84:94-7.
  279. Lamberg TS, Kivistö KT, Neuvonen PJ: Lack of effect of terfenadine on the pharmacokinetics of the CYP3A4 substrate buspirone. Pharmacol Toxicol 1999:84:165-9.
  280. Palkama VJ, Neuvonen PJ, Olkkola KT: Effect of itraconazole on the pharmacokinetics of bupivacaine enantiomers in healthy volunteers. Br J Anaesthesia 1999:83:659-61.
  281. Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT: Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin Pharmacol Ther 1999:66:33-9.
  282. Varis T, Kivistö KT, Backman J, Neuvonen PJ: Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone. Pharmacol Toxicol 1999:85:29-32.
  283. Wang JS, Wen X, Backman J, Taavitsainen P, Neuvonen PJ, Kivistö KT: Midazolam - hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole. Pharmacol Toxicol 1999:85:157-61.
  284. Kivistö KT, Laitila J, Mårtensson K, Neuvonen PJ: Determination of buspirone and 1-(2- pyrimidinyl)-piperazine (1-PP) in human plasma by capillary gas chromatography. Therapeutic Drug Monitoring 1999:21:317-21.
  285. Lapatto-Reiniluoto O, Kivistö KT, Neuvonen PJ: Effect of activated charcoal alone or given after gastric lavage in reducing the absorption of diazepam, ibuprofen and citalopram. Br J Clin Pharmacol 1999:48:148-53.
  286. Ahola T, Fellman V, Laaksonen R, Laitila J, Lapatto R, Neuvonen PJ, Raivio KO: Pharmacokinetics of intravenous N-acetylcysteine in preterm newborn infants. Eur J Clin Pharmacol 1999:55:645-50
  287. Isohanni MH, Neuvonen PJ, Olkkola KT: Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine. Pharmacol Toxicol 1999:84:143-6
  288. Lilja JJ, Kivistö KT, Neuvonen PJ: Grapefruit juice increases serum atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther 1999:66:118-27.
  289. Olkkola KT, Palkama VJ, Neuvonen PJ: Ritonavir`s role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology 1999:91:681-5
  290. Backman JT, Wang JS, Wen X, Kivistö KT, Neuvonen PJ: Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam. Clin Pharmacol Ther 1999:66:401-7.
  291. Wang JS, Backman JT, Wen X, Taavitsainen P, Neuvonen PJ, Kivistö KT: Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro. Pharmacol Toxicol 1999: 85: 201-5.
  292. Kivistö KT, Lilja JJ, Backman JT, Neuvonen PJ: Repeated consumption of grapefruit juice considerably increases plasma concentations of cisapride. Clin Pharmacol Ther 1999:66:448-53
  293. Villikka K, Kivistö KT, Mäenpää H, Joensuu H, Neuvonen PJ: Cytochrome P-450 inducing antiepileptics increase the clearance of vincristine in brain tumor patients. Clin Pharmacol Ther 1999:66:589-93
  294. 2000
  295. Varis T, Backman JT, Kivistö KT, Neuvonen PJ: Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone. Clin Pharmacol Ther 2000:67:215-21.
  296. Varis T, Kivistö KT, Neuvonen PJ: The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone, Eur J Clin Pharmacol 2000:56:57-60.
  297. Valtonen M, Tiula E, Backman JT, Neuvonen PJ: Elimination of meropenem during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 2000:45:701-4
  298. Saarenmaa E, Neuvonen PJ, Fellman V: Gestational age and birth weight effects on plasma clearance of fentanyl in newborn infants. J Ped 2000:136:767-770
  299. Kantola T, Backman JT, Niemi M, Kivistö KT, Neuvonen PJ: Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2000:56:225-229
  300. Lapatto – the ingestion of temazepam, verapamil and moclobemide: charcoal is superior to lavage. Br J Clin Pharmacol 2000:49:274-8.
  301. Wang JS, Backman JT, Taavitsainen P, Neuvonen PJ, Kivistö KT: Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metabolism and Disposition 2000:28:959-65.
  302. Lapatto-Reiniluoto O, Kivistö KT, Neuvonen PJ: Efficacy of activated charcoal versus gastric lavage half an hour after ingestion of moclobemide, temazepam and verapamil. Eur J Clin Pharmacol 2000;56:285-8
  303. Backman JT, Mäenpää J, Belle DJ, Wrighton SA, Kivistö KT, Neuvonen PJ: Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation. Clin Pharmacol Ther 2000:67:382-90.
  304. Jokinen MJ, Ahonen J, Neuvonen PJ, Olkkola KT: The effect of erythromycin, fluvoxamine and their combination on the pharmacokinetics of ropivacaine. Anesthesia and Analgesia 2000:91:1207- 12.
  305. Saarenmaa E, Neuvonen PJ, Rosenberg P, Fellman V: Morphine clearence and effects in newborn infants in relation to gestational age. Clin Pharmacol Ther 2000:68:160-6
  306. Varis T, Kivistö KT, Neuvonen PJ: Grapefruit juice can increase the plasma concentrations of oral methylprednisolone. Eur J Clin Pharmacol 2000:56:489-93.
  307. Lilja JJ, Kivistö KT, Backman JT, Neuvonen PJ: Effect of grapefruit juice dose on grapefruit juice- triazolam interaction: repeated consumption prolongs triazolam half-life. Eur J Pharmacol 2000:56:411-5
  308. Heikkinen T, Laine K, Neuvonen PJ, Ekblad U: The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin. Br J Obst Gyn 2000:107:770-5
  309. Palovaara, S, Kivistö KT, Tapanainen P, Manninen P, Neuvonen PJ, Laine K: Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1´-hydroxylation. Br J Clin Pharmacol 2000:50:333-337.
  310. Backman JT, Kyrklund C, Kivistö KT, Wang J-S, Neuvonen PJ: Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000:68:122-9
  311. Pohjola-Sintonen S, Kivistö KT, Vuori E, Lapatto-Reiniluoto O, Tiula E, Neuvonen PJ: Identification of drugs ingested in acute poisonings: correlation of patient history with drug analyses. Therapeutic Drug Monitoring 2000:22:749-752.
  312. Wang J-S, Backman JT, Kivistö KT, Neuvonen PJ: Effects of metronidazole on midazolam metabolism in vitro and in vivo. Eur J Clin Pharmacol 2000:56:555-559.
  313. Raaska K, Neuvonen PJ: Ciprofloxacin increases serum clozapine and N-desmethyl-clozapine: A study in patients with schizophrenia. Eur J Clin Pharmacol 2000:56:585-589.
  314. Varis T, Kivistö KT, Backman JT, Neuvonen PJ: The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal- suppressant effects. Clin Pharmacol Ther 2000:68:487-94.
  315. Lilja JJ, Kivistö KT, Neuvonen PJ: Duration of effect of grapefruit juice on the pharmacokinetics of the CYP 3A4 substrate simvastatin. Clin Pharmacol Ther 2000:68:384-90
  316. Kyrklund K, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ: Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 2000:68:592- 7.
  317. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivistö KT: Rifampin decreases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 2000:68:495-500.
  318. Niemi M, Kivistö KT, Backman J, Neuvonen PJ: Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride. Br J Clin Pharmacol 2000:50:591-5
  319. 2001
  320. Jokinen MJ, Ahonen J, Neuvonen PJ, Olkkola KT: Effect of clarithromycin and itraconazole on the pharmacokinetics of ropivacaine. Pharmacol Toxicol 2001:88:187-91
  321. Saarenmaa E, Huttunen P, Neuvonen PJ, Fellman V: Ketamine for procedural pain relief in newborn infants. Arch Dis Child Fetal Neonatal Ed. 2001:85:53-6
  322. Desta Z, Kivistö KT, Lilja JJ, Backman JT, Soukhova N, Neuvonen PJ, Flockhart DA: Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. Br J Clin Pharmacol 2001:52:399-407
  323. Kivistö KT, Wang J-S, Backman JT, Nyman L, Taavitsainen P, Anttila M, Neuvonen PJ: Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole. Eur J Clin Pharmacol 2001:57:37-42
  324. Wen X, Wang J-S, Kivistö KT. Neuvonen PJ, Backman JT: In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9(CYP2C9). Br J Clin Pharmacol 2001:52: 547-553
  325. Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivistö KT: Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 2001:69:194-200
  326. Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ: Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 2001:69:340-5
  327. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivistö KT: Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther 2001:69:400-6
  328. Niemi M, Neuvonen PJ, Kivistö KT: The cytochrome P450 3A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 2001:70:58-65
  329. Lapatto-Reiniluoto O, Kivistö KT, Neuvonen PJ: Activated charcoal alone and followed by whole- bowel irrigation in preventing the absorption of sustained-release drugs. Clin Pharmacol Ther 2001:70:255-260
  330. Villikka K, Varis T, Backman JT, Neuvonen PJ, Kivistö KT: Effect of methylprednisolone on CYP3A4 mediated drug metabolism in vivo. Eur J Clin Pharmacol 2001:57:457-460
  331. Valtonen M, Tiula E, Takkunen O, Backman JT, Neuvonen PJ: Elimination of piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 2001:48:881-885.
  332. Jokinen MJ, Olkkola KT, Ahonen J, Neuvonen PJ: Effect of rifampin and tobacco smoking on the pharmacokinetics of ropivacaine. Clin Pharmacol Ther 2001:70:344-350.
  333. Niemi M, Neuvonen PJ, Kivistö KT: Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 2001:70:439-445
  334. Wen X, Wang J-S, Backman JT, Kivistö KT, Neuvonen PJ: Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metabolism and Disposition 2001:29:1359-1361.
  335. Raaska K, Raitasuo V, Neuvonen PJ: Effect of influenza vaccination on serum clozapine and its main metabolite concentrations in patients with schizophrenia. Eur J Clin Pharmacol 2001:57:705- 708.
  336. 2002
  337. Wen X, Wang J-S, Neuvonen PJ, Backman JT: Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur J Clin Pharmacol 2002:57:799-804.
  338. Lamminpää A, Pukkala E, Teppo L, Neuvonen PJ: Cancer incidence among patients using antiepileptic drugs: a long-term follow-up of 28,000 patients. Eur J Clin Pharmacol 2002:58:137- 141.
  339. Wen X, Wang J-S, Backman JT, Laitila J, Neuvonen PJ: Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metabolism and Disposition 2002:30:631-635.
  340. Raaska K, Raitasuo V, Arstila M, Neuvonen PJ: Bacterial pneumonia can increase serum concentration of clozapine. Eur J Clin Pharmacol. 2002:58:321-2
  341. Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivistö KT: Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 2002:72:326- 32.
  342. Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivistö KT: Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P450 3A4 inhibitor itraconazole. Clin Pharmacol Ther 2002:72:362-9.
  343. Wang J-S, Wen X, Backman JT, Neuvonen PJ: Effect of albumin and cytosol on enzyme kinetics of tolbutamide hydroxylation and on inhibition of CYP2C9 by gemfibrozil in human liver microsomes. J Pharmacol Exp Ther 2002:302:43-49.
  344. Juntti-Patinen L, Neuvonen PJ: Drug-related deaths in a university hospital. Eur J Clin Pharmacol 2002:58:479-82.
  345. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ: Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 2002:72:685-91.
  346. Wang J-S, Neuvonen M, Wen X, Backman JT, Neuvonen PJ: Gemfibrozil inhibits CYP2C8- mediated cerivastatin metabolism in human liver microsomes. Drug Metabolism and Disposition 2002:30:1352-6.
  347. Raaska K, Raitasuo V, Neuvonen PJ: Therapeutic drug monitoring data: Risperidone does not increase serum clozapine concentration. Eur J Clin Pharmacol 2002:58:587-91.
  348. 2003
  349. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ: Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction of repaglinide with gemfibrozil. Diabetologia 2003:46:347-51.
  350. Pere P, Salonen M, Jokinen M, Rosenberg PH, Neuvonen PJ, Haasio J: Pharmacokinetics and effects of ropivacaine after axillary brachial plexus block in uremic and non-uremic patients. Anesthesia & Analgesia 2003:96:563-9.
  351. Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ: Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther 2003:73:192-8.
  352. Jokinen MJ, Olkkola KT, Ahonen J, Neuvonen PJ: Effect of ciprofloxacin on the pharmacokinetics of ropivacaine. Eur J Clin Pharmacol 2003:58:653-7.
  353. Malm H, Martikainen J, Klaukka T, Neuvonen PJ: Prescription drugs during pregnancy and lactation – a Finnish register-based study. Eur J Clin Pharmacol 2003:59:127-133.
  354. Malm H, Martikainen J, Klaukka T, Neuvonen PJ: Reseptilääkkeiden käyttö raskauden ja imetyksen aikana. Suomen Lääkärilehti 2003:58:2642-45.
  355. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ: Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 2003:73:538-44.
  356. Juntti-Patinen L, Neuvonen PJ: Lääkkeiden haittavaikutuksiin liittyvät kuolemat yliopistosairaalassa. Suomen Lääkärilehti 2003:58:179-181.
  357. Förster JG, Niemi TT, Aromaa U, Neuvonen PJ, Seppälä TA, Rosenberg PH: Epinephrine added to a lumbar epidural infusion of a small-dose ropivacaine-fentanyl mixture after arterial bypass surgery of the lower extremities. Acta Anaesthesiol Scand 2003:47:1106-13.
  358. Niemi M, Neuvonen M, Juntti-Patinen L, Backman JT, Neuvonen PJ: Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide: Clin Pharmacol Ther 2003:74:25-31.
  359. Hedman M, Neuvonen PJ, Neuvonen M, Antikainen M: Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia: Clin Pharmacol Ther 2003:74:178-85.
  360. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ: Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. Brit J Clin Pharmacol 2003:56:427-32.
  361. Niemi M, Backman JT, Granfors M, Laitila J, Neuvonen M, Neuvonen PJ: Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 2003:46:1319-23.
  362. Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ: Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther 2003:74:380-7.
  363. 2004
  364. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ: Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. Brit J Clin Pharmacol 2004:57:181-187.
  365. Mäenpää J, Tarpila A, Jouhikainen T, Ikävalko H, Löyttyniemi E, Perttunen K, Neuvonen PJ,Tarpila S: Magnesium hydroxide in ibuprofen tablet decreases the gastric mucosal tolerability of ibuprofen. J Clin Gastroenterol 2004:38:41-45.
  366. Lilja JJ, Niemi M, Neuvonen PJ: Rifampicin reduces plasma concentrations of celiprolol. Eur J Clin Pharmacol 2004:59:819-24.
  367. Raaska K, Raitasuo V, Laitila J, Neuvonen PJ: Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalised patients. Basic and Clinical Pharmacol Toxicol 2004:94:13-8.
  368. Ucar M, Neuvonen M, Luurila H, Dahlqvist R, Neuvonen PJ, Mjörndahl T: Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol 2004:59:879-82.
  369. Granfors MT, Backman JT, Laitila J, Neuvonen PJ: Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro. Br J Clin Pharmacol 2004:57:349-53.
  370. Niemi M, Kajosaari LI, Neuvonen M, Backman JT, Neuvonen PJ: The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. Br J Clin Pharmacol 2004:57:441-7.
  371. Hedman M, Neuvonen PJ, Neuvonen M, Holmberg C, Antikainen M: Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther 2004:75:101-9.
  372. Lilja JJ, Juntti-Patinen L, Neuvonen PJ: Orange juice substantially reduces the bioavailability of the β-adrenergic-blocking agent celiprolol. Clin Pharmacol Ther 2004:75:184-90.
  373. Granfors MT, Backman JT, Neuvonen M, Ahonen J, Neuvonen PJ: Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. Clin Pharmacol Ther 2004:75:331-341.
  374. Lilja JJ, Neuvonen M, Neuvonen PJ: Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol 2004:58:56-60.
  375. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, Eichelbaum M, Kivistö KT: High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004:14:429-440.
  376. Kajosaari LI, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ: Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. Br J Clin Pharmacol 2004:58:390-396.
  377. Niemi M, Backman JT, Neuvonen PJ: Effects of trimethoprim and rifampin on the pharmacokinetics of the CYP2C8 substrate rosiglitazone. Clin Pharmacol Ther 2004:76:239-249.
  378. Malm H, Martikainen J, Klaukka T, Neuvonen PJ: Prescription of hazardous drugs during pregnancy. Drug Safety 2004:27:899-908.
  379. Isohanni MH, Neuvonen PJ, Olkkola KT: Effect of itraconazole on the pharmacokinetics of inhaled lidocaine. Basic & Clinical Pharmacol and Toxicol 2004:95:120-123.
  380. Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ: Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its CYP1A2-mediated presystemic metabolism. Clin Pharmacol Ther 2004:76:598-606.
  381. 2005
  382. Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ: Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther 2005;77:404-414.
  383. Olkkola KT, Isohanni MH, Hamunen K, Neuvonen PJ: The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine. Anestehesia and Analgesia 2005;100:1352-6.
  384. Alaspää A, Kuisma MJ, Hoppu K, Neuvonen PJ: Prehospital administration of activated charcoal by EMS (Emergency Medical Services) is feasible and reduces delays in gastric decontamination after overdose. Ann Emerg Med 2005;45:207-212.
  385. Mustola ST, Baer GA, Neuvonen PJ, Toivonen KJ: Requirements of propofol at different end-points without adjuvant and during two different steady infusions of remifentanil. Acta Anaesthesiologica Scandinavica 2005;49:215-221.
  386. Lilja JJ, Backman JT, Neuvonen PJ: Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy volunteers. Br J Clin Pharmacol 2005;59:433-9.
  387. Niemi M, Neuvonen PJ, Hofmann U, Backman JT, Schwab M, Lütjohann D, von Bergmann K, Eichelbaum M, Kivistö KT: Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenetics and Genomics 2005;15:303-9.
  388. Niemi M, Backman JT, Juntti-Patinen L, Neuvonen M, Neuvonen PJ: Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. Brit Clin Pharmacol 2005:60:208-217.
  389. Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivistö KT, Neuvonen PJ: Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 2005:77:468-78.
  390. Tornio A, Pasanen MK, Laitila J, Neuvonen PJ, Backman JT: Comparison of 3-hydroxy-3- methylglutaryl coenzyme A (HMG-CoA)reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Basic & Clinical Pharmacol Toxicol 2005;97:104-8.
  391. Lilja JJ, Raaska K, Neuvonen PJ: Effects of orange juice on the pharmacokinetics of atenolol. Eur J Clin Pharmacol 2005:61:337-340.
  392. Backman JT, Luurila H, Neuvonen M, Neuvonen PJ: Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 2005:78:154-167.
  393. Lilja JJ, Laitinen K, Neuvonen PJ: Effects of grapefruit juice on the absorption of levothyroxine. Br J Clin Pharmacol 2005:60:337-341.
  394. Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT: Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic & Clinical Pharmacol Toxicol 2005:97:249-256.
  395. Isohanni MH, Ahonen J, Neuvonen PJ, Olkkola KT: Effect of ciprofloxacin on the pharmacokinetics of intravenous lidocaine. Eur J Anaesthesiol 2005:22:795-799.
  396. Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT: Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 2005:78:388-399.
  397. Granfors MT, Backman JT, Laitila J, Neuvonen PJ: Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin Pharmacol Ther 2005:78:400-411.
  398. Munsterhjelm E, Munsterhjelm NM, Niemi TT, Ylikorkala O, Neuvonen PJ, Rosenberg PH: Dose- dependent inhibition of platelet function by acetaminophen in volunteers. Anesthesiology 2005:103:712-717.
  399. Lilja JJ, Raaska K, Neuvonen PJ: Effects of grapefruit juice on the pharmacokinetics of acebutolol. Br J Clin Pharmacol 2005:60:659-663.
  400. Lilja JJ, Backman JT, Neuvonen PJ: Effect of itraconazole on the pharmacokinetics of atenolol. Basic & Clin Pharmacol & Toxicol 2005:97:395-398.
  401. Malm H, Klaukka T, Neuvonen PJ: Risks associated with selective serotonin reuptake inhibitors in pregnancy: a register-based study. Obstetrics and Gynecology 2005:106:1289-96.
  402. 2006
  403. Granfors MT, Wang JS, Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT: Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five HIV protease inhibitors in vitro. Basic and Clinical Pharmacology & Toxicology 2006:98:79-85.
  404. Jaakkola T, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ: Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol 2006:61:70-78.
  405. Juntti-Patinen L, Kuitunen T, Pere P, Neuvonen PJ: Drug-related visits to a district hospital emergency room. Basic & Clinical Pharmacol & Toxicol 2006:98:212-7.
  406. Kajosaari LI, Niemi M, Backman JT, Neuvonen PJ: Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 CYP3A4 and CYP2C8 substrate repaglinide. Clin Pharmacol Ther 2006:79:231-242.
  407. Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT: Effect of voriconazole on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther 2006:79:362-370.
  408. Kajosaari LI, Jaakkola T, Neuvonen PJ, Backman JT: Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. Eur J Clin Pharmacol 2006:62:217-223.
  409. Niemi TT, Neuvonen PJ, Rosenberg PH: Comparison of ropivacaine 2 mg/ml and prilocaine 5 mg/ml for i.v. regional anaesthesia in outpatient surgery. Br J Anaest 2006:96:640-4.
  410. Lilja JJ, Juntti-Patinen L, Neuvonen PJ: Effect of rifampicin on the pharmacokinetics of atenolol. Basic & Clinical Pharmacol & Toxicol 2006: 98:555-8.
  411. Seikku P, Raivio T, Jänne OA, Neuvonen PJ, Holmberg C: Methylprednisolone exposure in pediatric renal transplant patients. Amer J Transplantation 2006:6:1451-8.
  412. Hedman M, Antikainen M, Holmberg C, Neuvonen M, Eichelbaum M, Kivistö KT, Neuvonen PJ, Niemi M: Pharmacokinetics and response to pravastatin in paediatric patients with familiar hypercholesterolaemia and in paediatric cardic transplant recipients in relation to polymorphisms in SLCO1B1 and ABCB1 genes. Br J Clin Pharmacol 2006:61:706-15.
  413. Hynninen VV, Olkkola KT, Leino K, Lundgren S, Neuvonen PJ, Rane A, Valtonen M, Vyyryläinen H, Laine K: Effect of the antifungals voriconazole and fluconazole on the pharmacokinetics of S-(+) and R-(-)ibuprofen. Antimicrob Agents Chemother 2006:50:1967-72.
  414. Pasanen MK, Backman JT, Neuvonen PJ, Niemi M: Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur J Clin Pharmacol 2006:62:409-15.
  415. Backman JT, Granfors MT, Neuvonen PJ: Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. Eur J Clin Pharmacol 2006:62:451-61.
  416. Niemi M, Tornio A, Pasanen MK, Fredrikson H, Neuvonen PJ, Backman JT: Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. Eur J Clin Pharmacol 2006:62:463-72.
  417. Jaakkola T, Backman JT, Neuvonen M, Niemi M, Neuvonen PJ: Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone. Eur J Clin Pharmacol 2006;62:503-9.
  418. Jaakkola T, Laitila J, Neuvonen PJ, Backman J: Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: Potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol 2006:99:44-51.
  419. Isohanni M, Neuvonen PJ, Olkkola KT: Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine. Basic Clin Pharmacol Toxicol 2006:99:168-172.
  420. Munsterhjelm E, Niemi TT, Ylikorkala O, Neuvonen PJ, Rosenberg PH: Influence on platelet aggregation of i.v. parecoxib and acetaminophen in healthy volunteers. Brit J Anaesthesia 2006:97:226-31.
  421. Tornio A, Neuvonen PJ, Backman JT: The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone. Eur J Clin Pharmacol 2006:62:645-51.
  422. Niemi M, Arnold KA, Backman JT, Pasanen MK, Gödtel-Armbrust U, Wojnowski L, Zanger UM, Neuvonen PJ, Eichelbaum M, Kivistö KT, Lang T: Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenetics & Genomics 2006:16:801-8.
  423. Backman JT, Karjalainen MJ, Neuvonen M, Laitila J, Neuvonen PJ: Rofecoxib is a potent inhibitor of cytochrome P450 1A2: Studies with tizanidine and caffeine in healthy subjects. Brit J Clin Pharmacol 2006:62:345-57.
  424. Niemi M, Pasanen MK, Neuvonen PJ: SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 2006:80:356-66.
  425. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M: SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenetics & Genomics 2006:16:873-9.
  426. Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT: Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. Clin Pharmacol Ther 2006:80:502-8.
  427. Rautiainen H, Färkkilä M, Neuvonen M, Sane T, Karvonen A-L, Nurmi H, Kärkkäinen P, Neuvonen PJ, Backman JT: Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis. Alimentary Pharmacol & Therapeutics 2006:24:1545-52.
  428. Karjalainen MJ, Neuvonen PJ, Backman JT: Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: Implications for in vitro prediction of drug interaction. Drug Metabolism and Disposition 2006:34:2091-6.
  429. 2007
  430. Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT: Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects. Brit J Clin Pharmacol 2007:63:116-20.
  431. Jokinen MJ, Neuvonen PJ, Lindgren L, Höckerstedt K, Sjövall J, Breuer O, Askemark Y, Ahonen J, Olkkola KT: Pharmacokinetics of ropivacaine in patients with chronic end-stage liver disease. Anesthesiology 2007:106:43-55.
  432. Lilja JJ, Niemi M, Fredrikson H, Neuvonen PJ: Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br J Clin Pharmacol 2007:63:732-40.
  433. Becquemont L, Neuvonen M, Demolis JL, Verstuyft C, Jaillon P, Neuvonen PJ, Funck-Brentano C: Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. Clin Pharmacol Ther 2007:81:679-84.
  434. Lilja JJ, Backman JT, Neuvonen PJ: Effect of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine and midazolam – probes of CYP2C9, CYP1A2 and CYP3A4. Clin Pharmacol Ther 2007:81:833-39.
  435. Tornio A, Niemi M, Neuvonen PJ, Backman JT: Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen. Eur J Clin Pharmacol 2007:63:463-9.
  436. Seitsonen ER, Cohen-Laroque ES, van Gils MJ, Korttila KT, Neuvonen PJ, Yli-Hankala AM: Propofol versus alfentanil to prevent movement responses during uterine curettage. Acta Anaesthesiol Scand 2007:51:751-8.
  437. Schneider B, Gerdsen R, Plat J, Dullens S, Björkhem I, Diczfalusy U, Neuvonen PJ, Bieber T, von Bergman K, Lütjohann D: Effects of high dose itraconazole treatment on lipoproteins in men. Int J Clin Pharmacol Ther 2007:45:377-84.
  438. Karjalainen MJ, Neuvonen PJ, Backman JT: Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation. Eur J Clin Pharmacol 2007:63:829-36.
  439. Saari TI, Laine K, Bertilsson L, Neuvonen PJ, Olkkola KT: Voriconazole and fluconazole increase the exposure to oral diazepam. Eur J Clin Pharmacol 2007:63:941-9.
  440. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M: Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007:82:726-33.
  441. Hynninen VV, Olkkola KT, Leino K, Lundgren S, Neuvonen PJ, Rane A, Valtonen M, Laine K: Effect of voriconazole on the pharmacokinetics of diclofenac. Fundamental & Clinical Pharmacol 2007:21:651-6.
  442. 2008
  443. Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M: No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. Br J Clin Pharmacol 2008:65:78-86.
  444. Pasanen MK, Neuvonen PJ, Niemi M: Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 2008:9:19-33.
  445. Tornio A, Niemi M, Neuvonen PJ, Backman JT: Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metabolism and Disposition 2008:36:73-80.
  446. Backman JT, Schröder MT, Neuvonen PJ: Effect of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine. Eur J Clin Pharmacol 2008:64:17- 24.
  447. Saari TI, Laine K, Neuvonen M, Neuvonen PJ, Olkkola KT: Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. Eur J Clin Pharmacol 2008:64:25-30.
  448. Fanta S, Niemi M, Jönsson S, Karlsson MO, Holmberg C, Neuvonen PJ, Hoppu K, Backman JT: Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphism. Pharmacogenetics and Genomics 2008:18:77-90.
  449. Hynninen VV, Olkkola KT, Bertilsson L, Kurkinen K, Neuvonen PJ, Laine KT: Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine. Clin Pharmacol Ther 2008:83:342-8.
  450. Rodríguez-Antona C, Niemi M, Backman TT, Kajosaari L, Neuvonen PJ, Robledo M, Ingelman- Sundberg M: Characterization of novel CYP2C8 haplotypes causing altered paclitaxel and repaglinide metabolism. Pharmacogenomics Journal 2008:8:268-77.
  451. Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M: Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J Clin Pharmacol 2008:48:311-21.
  452. Karjalainen MJ, Neuvonen PJ, Backman JT: Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo. Eur J Clin Pharmacol 2008:64:511-9.
  453. Keskitalo JE, Kurkinen KJ, Neuvonen PJ, Niemi M: ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 2008:84:457-61.
  454. Karjalainen MJ, Neuvonen PJ, Backman JT: In vitro inhibition of CYP1A2 by model inhibitors, anti- inflammatory analgesics and female sex steroids – predictability of in vivo interaction. Basic & Clin Pharmacol & Toxicol 2008:103:157-65.
  455. Tornio A, Niemi M, Neuvonen M, Laitila J, Kalliokoski A, Neuvonen PJ, Backman JT: The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: Evidence for mechanism-based inhibition of CYP2C8 in vivo. Clin Pharmacol Ther 2008:84:403-411.
  456. Neuvonen M, Neuvonen PJ: Determination of oxycodone, noroxycodone, oxymorphone and noroxymorphone in human plasma by liquid chromatography-electrospray-tandem mass spectrometry. Therapeutic Drug Monitoring 2008:30:333-40.
  457. Liukas A, Kuusniemi K, Aantaa R, Virolainen P, Neuvonen M, Neuvonen PJ, Olkkola KT: Plasma concentrations of oral oxycodone are greatly increased in the elderly. Clin Pharmacol Ther 2008:84:462-7.
  458. Kalliokoski A, Backman JT, Kurkinen K, Neuvonen PJ, Niemi M: Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. Clin Pharmacol Ther, 2008:84:488-496.
  459. Kallio, H, Niskanen ML, Havia M, Neuvonen PJ, Rosenberg PH, Kentala E: I.V. ropivacaine compared with lidocaine for the treatment of tinnitus. Br J Anaesth 2008;101:261-5.
  460. Heiskanen T, Backman JT, Neuvonen M, Kontinen VK, Neuvonen PJ, Kalso E: Itraconazole, a potent inhibitor of P-glycoprotein, moderately increases plasma concentrations of oral morphine. Acta Anaesthesiol Scand 2008:52:1319-26.
  461. Pasanen MK, Miettinen TA, Gylling H, Neuvonen PJ, Niemi M: Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenetics and Genomics 2008;18:921-6.
  462. Ruokoniemi P, Helin-Salmivaara A, Klaukka T, Neuvonen PJ, Huupponen R: Shift of statin use towards the elderly in 1995-2005: a nation-wide register study in Finland. Br J Clin Pharmacol 2008:66:405-410.
  463. Kalliokoski A, Backman JT, Neuvonen PJ, Niemi M: Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Pharmacogenetics and Genomics 2008:18:937-942.
  464. Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M: The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range. Br J Clin Pharmacol 2008:66:818-825.
  465. Helin-Salmivaara A, Lavikainen P, Korhonen MJ, Halava H, Junnila SYT, Kettunen R, Neuvonen PJ, Martikainen JE, Ruokoniemi P, Saastamoinen LK, Virta L, Huupponen R: Long-term persistence with statin therapy: A natiowide register study in Finland. Clinical Therapeutics 2008:30 Theme issue:2228-2240.
  466. 2009
  467. Hynninen VV, Olkkola KT, Neuvonen PJ, Laine K: Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib. Eur J Clin Pharmacol 2009:65:89-95.
  468. Hagelberg NM, Nieminen TH, Saari TI, Neuvonen M, Neuvonen PJ, Laine K, Olkkola KT: Voriconazole drastically increases exposure to oral oxycodone. Eur J Clin Pharmacol 2009:65:263- 271.
  469. Hynninen VV, Olkkola KT, Bertilsson L, Kurkinen KJ, Korhonen T, Neuvonen PJ, Laine K: Voriconazole increases while itraconazole decreases plasma meloxicam concentrations. Antimicrob Agents Chemother. 2009:53:587-592.
  470. Nieminen TH, Hagelberg NM, Saari TI, Pertovaara A, Neuvonen M, Laine K, Neuvonen PJ, Olkkola KT: Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology 2009:110:1371-1378.
  471. Aitta-aho T, Vekovischeva OY, Neuvonen PJ, Korpi ER: Reduced benzodiazepine tolerance, but increased flumazenil-precipitated withdrawal in AMPA-receptor GluR-A subunit-deficient mice. Pharmacology, Biochemistry and Behaviour 2009:92:283-290.
  472. Keskitalo JE, Kurkinen KJ, Neuvonen M, Backman JT, Neuvonen PJ, Niemi M: No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. Br J Clin Pharmacol 2009:68:207-213.
  473. Xiang X, Han Y, Neuvonen M, Pasanen MK, Kalliokoski A, Backman JT, Laitila J, Neuvonen PJ, Niemi M: Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans. Pharmacogenetics and Genomics 2009:19:447-457.
  474. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M: ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2009:86:197-203.
  475. Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M: Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin, and simvastatin. Pharmacogenomics 2009:10:1217-1224.
  476. Backman JT, Honkalammi J, Neuvonen M, Kurkinen KJ, Niemi M, Tornio A, Neuvonen PJ: CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: Estimation of CYP2C8 half-life using repaglinide as an in vivo probe. Drug Metabolism and Disposition, 2009:37:2359-2366.
  477. 2010
  478. Riedmaier S, Klein K, Hofmann U, Keskitalo JE, Neuvonen PJ, Schwab M, Niemi M, Zanger UM: UDP-glucuronyltransferase (UGT)-polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther 2010:87:65-73.
  479. Grönlund J, Saari T, Hagelberg N, Martikainen IK, Neuvonen PJ, Olkkola KT, Laine K: Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone. J Clin Pharmacol 2010:50:101-108.
  480. Xiang X, Han Y, Neuvonen M, Laitila J, Neuvonen PJ, Niemi M: High performance liquid chromatography–tandem mass spectrometry for the determination of bile acid concentrations in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2010:878:51-60.
  481. Lemberg KK, Heiskanen TE, Neuvonen M, Kontinen VK, Neuvonen PJ, Dahl ML, Kalso EA: Does co-administration of paroxetine change oxycodone analgesia: An interaction study in chronic pain patients. Scand Journal of Pain 2010:1:24-33.
  482. Saari TI, Grönlund J, Hagelberg NM, Neuvonen M, Laine K, Neuvonen PJ, Olkkola KT: Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. Eur J Clin Pharmacol 2010:66:387-397.
  483. Tapaninen T, Neuvonen PJ, Niemi M: Rifampicin reducses the plasma concentrations and the renin- inhibiting effect of aliskiren. Eur J Clin Pharmacol 2010:66:497-502.
  484. Hagelberg NM, Peltoniemi MA, Saari TI, Kurkinen KJ, Laine K, Neuvonen PJ, Olkkola KT: Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine. Eur J Pain 2010:14:625-629.
  485. Grönlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Olkkola KT, Laine K: Exposure to of oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol 2010:70:78-87.
  486. Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT: Gemfibrozil markedly increases the plasma concentrations of montelukast; a previously unrecognized role for CYP2C8 in the metabolism of montelukast. Clin Pharmacol Ther 2010:88:223-230.
  487. Tapaninen T, Neuvonen PJ, Niemi M: Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren. Eur J Clin Pharmacol 2010;66:865-870.
  488. Nieminen TH, Hagelberg NM, Saari TI, Neuvonen M, Laine K, Neuvonen PJ, Olkkola KT: St John`s wort greatly reduces the concentrations of oral oxycodone. Eur J Pain 2010:14:854-859.
  489. Tapaninen T, Neuvonen PJ, Niemi M: Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren. Clin Pharmacol Ther 2010:88:339-342.
  490. Nieminen TH, Hagelberg NM, Saari TI, Neuvonen M, Neuvonen PJ, Laine K, Olkkola KT: Grapefruit juice enhances the exposure to oral oxycodone. Basic & Clin Pharmacol & Toxicol 2010:107:782-788.
  491. Nieminen TH, Hagelberg NM, Saari TI, Neuvonen M, Neuvonen PJ, Laine K, Olkkola KT: Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. Eur J Clin Pharmacol 2010:66:977-085.
  492. Niiya T, Litonius E, Petäjä L, Neuvonen PJ, Rosenberg PH: Intravenous lipid emulsion sequesters amiodarone in plasma and eliminates its hypotensive action in pigs. Annals of Emergency Medicine 2010:56(4):402-408.e2
  493. 2011
  494. Liukas A, Kuusniemi K, Aantaa R, Virolainen P, Neuvonen M, Neuvonen PJ, Olkkola KT: Elimination of intravenous oxycodone in the elderly: A pharmacokinetic study in postoperative orthopaedic patients of different age groups. Drugs & Aging 2011:28:41-50.
  495. Merivirta RM, Kuusniemi KS, Hurme SA, Neuvonen PJ, Rautakorpi PJ, Olkkola KT, Leino KA: Plasma levels of bupivacaine and its metabolites after subacromial infusions in concentrations 2.5 or 5.0 mg/ml. Acta Anaesthesiol Scand 2011:55:228-233.
  496. Karonen T, Neuvonen PJ, Backman JT: The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast. Eur J Clin Pharmacol 2011:67:151-155.
  497. Liukas A, Kuusniemi K, Aantaa R, Virolainen P, Niemi M, Neuvonen PJ, Olkkola KT: Pharmacokinetics of intravenous paracetamol in elderly patients. Clin Pharmacokin 2011:50:121- 129.
  498. Tapaninen T, Backman JT, Kurkinen KJ, Neuvonen PJ, Niemi M: Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren. J Clin Pharmacol 2011:51:359-367.
  499. Grönlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Olkkola KT, Laine K: Miconazole oral gel increases the exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4. Antimicrobial Agents and Chemotherapy 2011:55:1063-1067.
  500. Grönlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Laine K, Olkkola KT: Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: A randomized, three-phase, crossover, placebo-controlled study. Clinical Drug Investigation 2011:31:143-153.
  501. Honkalammi J, Niemi M, Neuvonen PJ, Backman JT: Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans. Clin Pharmacol Ther 2011:89(4):579-586.
  502. Iirola T, Vilo S, Aantaa R, Wendelin-Saarenhovi M, Neuvonen PJ, Scheinin M, Olkkola KT: Dexmedetomidine inhibits gastric emptying and oro-caecal transit in healthy volunteers. Br J Anaesthesia 2011:106:522-527.
  503. Tapaninen T, Neuvonen PJ, Niemi M: Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. Brit J Clin Pharmacol 2011:71:718-26.
  504. Liukas A, Hagelberg NM, Kuusniemi K, Neuvonen PJ, Olkkola KT: Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers. J Clin Psychopharmacol 2011:31:302-308.
  505. Filppula AM, Laitila J, Neuvonen PJ, Backman JT: Reevaluation of the microsomal metabolism of montelukast – major contribution by CYP2C8 at clinically relevant concentrations. Drug Metabolism and Disposition 2011:39:904-11.
  506. Peltoniemi MA, Saari TI, Hagelberg NM, Reponen P, Turpeinen M, Laine K, Neuvonen PJ, Olkkola KT: Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine. Clin Pharmacol Ther 2011:90(2):296-302.
  507. Tuuminen R, Syrjälä S, Krebs R, Keränen MAI, Koli K, Abo-Ramadan U, Neuvonen PJ, Tikkanen JM, Nykänen AI, Lemström KB: Donor simvastatin treatment abolishes rat cardiac allograft ischemia/reperfusion injury and chronic rejection through microvascular protection. Circulation 2011:124(10):1138-1150.
  508. Honkalammi J, Niemi M, Neuvonen PJ, Backman JT: Dose-dependent interaction between gemfibrozil and repaglinide in humans: Strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses. Drug Metabolism & Dispos 2011:39(10)1977-1986.
  509. Xiang X, Vakkilainen J, Backman JT, Neuvonen PJ, Niemi M: No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of ursodesoxycholic acid. Eur J Clin Pharmacol 2011:67:1159-67.
  510. 2012
  511. Karonen T, Neuvonen PJ, Backman JT: CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast. Brit J Clin Pharmacol 2012:73(2):257-267.
  512. Saari TI, Ihmsen H, Neuvonen PJ, Olkkola KT, Schwilden H: Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. Brit J Anaesthesia 2012:108(3):491-8.
  513. Xiang X, Backman JT, Neuvonen PJ, Niemi M: Gender, but not CYP7A1 or SLCO1B1 polymorphism, affects the fasting plasma concentrations of bile acids in humans. Basic & Clinical Pharmacol & Toxicol 2012:110:245-52.
  514. Litonius E, Niiya T, Neuvonen PJ, Rosenberg PH: No antidotal effect of intravenous lipid emulsion in experimental amitriptyline intoxication despite significant entrapment of amitriptyline. Basic & Clin Pharmacol & Toxicol 2012:110:378-83.
  515. Litonius E, Niiya T, Neuvonen PJ, Rosenberg PH: Intravenous lipid emulsion only minimally influences bupivacaine and mepivacaine distribution in plasma and does not enhance recovery from intoxication in pigs. Anesthesia and Analgesia 2012;114(4):901-6.
  516. Filppula AM, Laitila J, Neuvonen PJ, Backman JT: Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol 2012;165:2787- 98.
  517. Honkalammi J, Niemi M, Neuvonen PJ, Backman JT: Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses. Clin Pharmacol Ther 2012:91(5):846-55.
  518. Karonen T, Laitila J, Miemi M, Neuvonen PJ, Backman J: Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases plasma concentrations of zafirlukast. Eur J Clin Pharmacol 2012;68:681-8.
  519. Litonius E, Tarkkila P, Neuvonen PJ, Rosenberg PH: Effect of intravenous lipid emulsion on bupivacaine plasma concentration in humans. Anaesthesia 2012:67(6):600-5.
  520. Rikalainen-Salmi R, Förster JG, Mäkelä K, Virolainen P, Leino KA, Pitkänen MT, Neuvonen PJ, Kuusniemi KS: Local infiltration analgesia compared with intrathecal morphine in total hip arthroplasty patients. Acta Anaesthesiol Scand 2012:56:695-705.
  521. Peltoniemi MA, Saari TI, Hagelberg NM, Laine K, Neuvonen PJ, Olkkola KT: S-ketamine concentrations are greatly increased by grapefruit juice. Eur J Clin Pharmacol 2012;68:979-86.
  522. Tarkiainen EK, Backman JT, Neuvonen M, Neuvonen PJ, Schwab M, Niemi M. Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans. Clin Pharmacol Ther 2012;92(1):68-71.
  523. Litonius E, Lokajova J, Yohannes G, Neuvonen PJ, Holopainen JM, Rosenberg PH, Wiedmer SK: In vitro and in vivo entrapment of bupivacaine by lipid dispersions. Journal of Chromatography A 2012;1254:125-31.
  524. Kokki M, Gonzalez Franco M, Raatikainen K, Välitalo P, Sankilampi U, Heinonen S, Neuvonen PJ, Kokki H: Intravenous oxycodone for pain relief in the first stage of labor – Maternal pharmacokinetics and neonatal exposure. Basic & Clinical Pharmacology & Toxicology 2012;111:182-8.
  525. Sahi H, Koljonen V, Böhling T, Neuvonen PJ, Vainio H, Lamminpää A, Kyyronen P, Pukkala E: Increased incidence of Merkel cell carcinoma among younger statin users. Cancer Epidemiology 2012:36:421-4.
  526. Hiller A, Helenius I, Nurmi E, Neuvonen PJ, Kaukonen M, Hartikainen T, Korpela R, Taivainen T, Meretoja OA: Acetaminophen improves analgesia but does not reduce opioid requirement after major spine surgery in children and adolescents. SPINE 2012:37:E1225-E1231.
  527. Peltoniemi MA*, Saari TI*, Hagelberg NM, Laine K, Kurkinen KJ, Neuvonen PJ, Olkkola KT: Rifampicin has a profound effect on the pharmacokinetics of oral S-ketamine and less on intravenous S-ketamine. Basic & Clinical Pharmacology & Toxicology 2012:111:325-32.
  528. Peltoniemi MA, Saari TI, Hagelberg NM, Laine K, Neuvonen PJ, Olkkola KT: St John´s Wort greatly decreases the plasma concentrations of oral S-ketamine. Fundamental & Clinical Pharmacology 2012:26:743-50.
  529. Helin-Salmivaara A, Korhonen MJ, Lehenkari P, Junnila SYT, Neuvonen PJ, Ruokoniemi P, Huupponen R: Statins and hip fracture prevention – a population based cohort study in women. PlosOne 2012:7(10):e48095; doi:10.1371/journal.pone.0048095
  530. Lippert J, Brosch M, von Kampen O, Meyer M, Siegmund HU, Schafmayer C, Becker T, Laffert B, Görlitz L, Schreiber S, Neuvonen PJ, Niemi M, Hampe J, Kuepfer L: A mechanistic, model-based approach to safety assessment in clinical development. CPT: Pharmacometrics & Systems Pharmacology 2012:1, e13; doi:10.1038/psp.2012.14
  531. Kokki M, Broms S, Eskelinen M, Neuvonen PJ, Halonen T, Kokki H: The analgesic concentration of oxycodone with co-administration of paracetamol – a dose-finding study in adult patients undergoing laparoscopic cholecystectomy. Basic & Clinical Pharmacology & Toxicology 2012:111:391-5.
  532. 2013
  533. Tapaninen T, Karonen T, Backman JT, Neuvonen PJ, Niemi M: SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren. Pharmacogenetics and Genomics 2013:23(1):19-24.
  534. Filppula AM, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT: Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: Variability in CYP2C8 activity may alter plasma concentrations and response. Drug Metabolism and Disposition 2013:41:50-59.
  535. Meskanen K, Ekelund H, Laitinen J, Neuvonen PJ, Haukka J, Panula P, Ekelund J: A randomized clinical trial of Histamine H2 receptor antagonism in the treatment-resistant schizophrenia. J Clin Psychopharmacol 2013:33(4):472-8.
  536. Hagelberg NM, Saarikoski T, Saari TI, Neuvonen M, Neuvonen PJ, Turpeinen M, Scheinin M, Laine K, Olkkola KT: Ticlopidine inhibits both O-demethylation and renal clearance of tramadol, increasing the exposure to it, but itraconazole has no marked effect on the ticlopidine-tramadol interaction. Eur J Clin Pharmacol 2013:69:867-75.
  537. Holmberg MT, Tornio A, Joutsi-Korhonen L, Neuvonen M, Neuvonen PJ, Lassila R, Niemi M, Backman JT: Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects. Brit J Clin Pharmacol 2013:75(6):1488-96.
  538. Saarikoski T, Saari TI, Hagelberg NM, Neuvonen M, Neuvonen PJ, Scheinin M, Olkkola KT, Laine K. Rifampicin markedly decreases the exposure to oral and intravenous tramadol. Eur J Clin Pharmacol 2013:69:1293-1301.
  539. Keski-Nisula J, Pesonen E, Olkkola KT, Peltola K, Neuvonen PJ, Tuominen N, Sairanen H, Andersson S, Suominen PK: Methylprednisolone in neonatal cardiac surgery: Reduced inflammation without improved clinical outcome. The Annals of Thoracic Surgery 2013:95:2126-32.
  540. Krauss M, Burghaus R, Lippert J, Niemi M, Neuvonen P, Schuppert A, Willmann S, Kuepfer L, Görlitz L: Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification. In Silico Pharmacology, 2013, 1:6, http://www.in-silico- pharmacology.com/content/1/1/6 ;(11 April 2013) doi:10.1186/2193-9616-1-6.
  541. Frechen S, Junge L, Saari TI, Suleiman AA, Rokitta D, Neuvonen PJ, Olkkola KT, Fuhr U: A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole. Clinical Pharmacokinetics 2013:52(9)763-81.
  542. Heinonen JA, Litonius E, Backman JT, Neuvonen PJ, Rosenberg PH: Intravenous lipid emulsion entraps amitriptyline into plasma and can lower its brain concentration – an experimental intoxication study in pigs. Basic & Clinical Pharmacology & Toxicology 2013:113:193-200.
  543. Filppula AM, Tornio A, Niemi M, Neuvonen PJ, Backman JT: Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite. Clin Pharmacol & Therap 2013:94(3):383-93.
  544. 2014
  545. Puustinen J, Lähteenmäki R, Polo-Kantola P, Salo P, Vahlberg T, Lyles A, Neuvonen PJ, Partinen M, Räihä I, Kivelä SL: Effect of withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotic agents on cognition in older adults. Eur J Clin Pharmacol 2014:70:319-29.
  546. Holmberg MT, Tornio A, Neuvonen M, Neuvonen PJ, Backman JT, Niemi M: Grapefruit juice inhibits the metabolic activation of clopidogrel. Clin Pharmacol & Therap 2014:95(3):307-13.
  547. Lähteenmäki R, Puustinen J, Vahlberg T, Lyles A, Neuvonen PJ, Partinen M, Räihä I, Kivelä S-L: Melatonin for sedative withdrawal in older patients with primary insomnia: a randomised double- blind placebo-controlled trial. Br J Clin Pharmacol 2014:77(6):975-85.
  548. Filppula AM, Neuvonen PJ, Backman JT: In Vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metabolism and Disposition 2014:42(7):1202-9.
  549. Tornio A, Filppula AM, Kailari O, Neuvonen M, Nyrönen TH, Tapaninen T, Neuvonen PJ, Niemi M, Backamn JT: Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. Clin Pharmacol & Therap 2014:96(4):498-507.
  550. Nurminen J, Puustinen J, Lähteenmäki R, Vahlberg T, Lyles A, Partinen M, Räihä I, Neuvonen PJ, Kivelä S-L: Handgrip strength and balance in older adults following withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotics. BMC Geriatrics 2014:14:121, doi:10.1186/1471- 2318-14-121. http://www.biomedcentral.com/1471-2318/14/121 (10 pages)
  551. Mäenpää J, Volotinen-Maja M, Kautiainen H, Neuvonen M, Niemi M, Neuvonen PJ, Backman JT: Paroxetine markedly increases plasma concentrations of ophthalmic timolol; CYP2D6 inhibitors may increase the risk of cardiovascular adverse effects of 0.5% timolol eye drops. Drug Metabolism and Disposition 2014:42:2068-2076, + Supplemental material 1: table and 4 figures.
  552. 2015
  553. Keski-Nisula J, Suominen PK, Olkkola KT, Peltola K, Neuvonen PJ, Tynkkynen P, Salminen JT, Andersson S, Pesonen E: Effect of timing and route of methylprednisolone administration during pediatric cardiac surgical procedures. The Annals of Thoracic Surgery 2015:99;180-5.
  554. Saarikoski T, Saari TI, Hagelberg NM, Backman JT, Neuvonen PJ, Scheinin M, Olkkola KT and Laine K. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol. Eur J Clin Pharmacol 2015:71(3):321-7.
  555. Holmberg MT, Tornio A, Hyvärinen H, Neuvonen M, Neuvonen PJ, Backman JT, Niemi M: Effect of grapefruit juice on the bioactivation of prasugrel. Br J Clin Pharmacol 2015:80(1):139-45.
  556. Tarkiainen EK, Holmberg MT, Tornio A, Neuvonen M, Neuvonen PJ, Backman JT, Niemi M: Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing hydrolysis in humans. Clin Pharmacol & Therap 2015:97(6):650-8.
  557. Tarkiainen EK, Tornio A, Holmberg MT, Launiainen T, Neuvonen PJ, Backman JT, Niemi M: Effect of carboxylesterase 1 c.428G>A single nucleotide variation on the pharmacokinetics of quinapril and enalapril. Br J Clin Pharmacol 2015:80(5):1131-8.
  558. Tornio A, Vakkilainen J, Neuvonen M, Backman JT, Neuvonen PJ, Niemi M: SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid. Pharmacogenetics and Genomics 2015:25(8):382-7.
  559. Lapatto-Reiniluoto O, Patinen L, Niemi M, Backman JT, Neuvonen PJ: Drug-related inadvertent deaths in a university hospital – a declining trend. Basic & Clin Pharmacol & Toxicol 2015:117:421- 6.
  560. Itkonen MK, Tornio A, Neuvonen M, Neuvonen PJ, Niemi M, Bacman JT: Clopidogrel has no meaningful effect on the pharmacokinetics of the OATP1B1 and CYP3A4 substrate simvastatin: a crossover study in healthy volunteers. Drug Metabolism and Disposition 2015:43(11):1655-60.
  561. 2016
  562. Lapatto-Reiniluoto O, Niemi M, Backman J, Neuvonen PJ: Lääkkeiden aiheuttamat kuolemantapaukset ovat vähentyneet yliopistosairaalassa. Suomen Lääkärilehti 2016:71(5):295-301.
  563. Keski-Nisula J, Pesonen E, Olkkola KT, Ahlroth T, Puntila J, Andersson S, Neuvonen PJ, Suominen PK: High-dose methylprednisolone has no benefit over moderate dose for the correction of Tetralogy of Fallot. The Annals of Thoracic Surgery 2016:102(3):870-6.
  564. Itkonen MK, Tornio A, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT: Clopidogrel markedly increases plasma concentrations of the CYP2C8 substrate pioglitazone. Drug Metabolism and Disposition 2016:44:1364-71.
  565. Fihlman M, Hemmilä T, Hagelberg NM, Kuusniemi K, Backman JT, Laitila J, Laine K, Neuvonen PJ, Olkkola KT, Saari TI: Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction. Eur J Clin Pharmacolögy 2016:71:1363-71.
  566. Hagelberg NM, Fihlman M, Hemmilä T, Backman JT, Laitila J, Neuvonen PJ, Laine K, Olkkola KT, Saari T: Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects. Pharmacology Research and Pespectives 2016; accepted 30.9
  567. Suominen PK, Keski-Nisula J, Ojala T, Rautiainen P, Jahnukainen T, Hästbacka J, Neuvonen PJ, Pitkänen O, Niemelä J, Kaskinen A, Salminen J, Lapatto R: Stress-dose corticosteroid versus placebo in neonatal cardiac surgery: A randomized controlled trial. Annals of Thoracic Surgery, submitted for publication.
  568. Lähteenmäki R, Neuvonen PJ, Puustinen J, Vahlberg T, Partinen M, Räihä I, Kivelä S-L: Perceived sleep and quality of life before and after withdrawal from long-term sedative hypnotics in older people with insomnia. Brit. J. Clin. Pharmacol. Submitted for publication.

Review Articles

  1. Neuvonen PJ: Studies on the cardiovascular effects of some diuretics. M.D. Thesis, Helsinki 1971
  2. Niemelä S, Vapaatalo H, Neuvonen PJ: Prostaglandiinien biologinen ja farmakologinen merkitys (Biological and pharmacological significance of prostaglandins). Duodecim 1973:89:19-26
  3. Neuvonen PJ, Gothoni G: Interaktion mellan järn och tetracycliner – ett praktiskt problem. Hässle Information (Sweden) 1973:9:1-5
  4. Neuvonen PJ: Lääkkeiden aiheuttamat maksavauriot (Drug-induced liver diseases). Duodecim 1974:90:1360-1365
  5. Neuvonen PJ: Läkemedelsbestämningar och deras kliniska betydelse (The clinical significance of measuring drug concentrations in blood). Finska Läkaresällskapets Handlingar 1975:119:119-125
  6. Neuvonen PJ: Interactions with the absorption of tetracyclines. Drugs 1976:11:45-54
  7. Neuvonen PJ: Interactions with the absorption of tetracycline. New Ethicals and Medical Progress. 1976:13:69-79
  8. Neuvonen PJ: Diureetit, luku 41 oppikirjaan Farmakologia (Chapter Diuretics in the Textbook of Pharmacology, eds Tuomisto and Paasonen) Helsinki 1978:LOATS: pp 398-410
  9. Neuvonen PJ: Lääkehoidon erityispiirteitä vanhuksilla. Diagnosis 1976:4:14-22
  10. Neuvonen PJ: Lääkeaineiden aiheuttama lupussyndrooma. Diagnosis 1977:4:145-152
  11. Neuvonen PJ: Pharmacokinetic aspects of acute intoxications. Symposium on Toxicology, Tampere 1978
  12. Elonen E, Neuvonen PJ: Myrkytysten spesifinen hoito (The treatment of poisonings with specific antidotes). Duodecim 1978:94:1628-1639
  13. Neuvonen PJ: Diureettien kliinistä farmakologiaa. Vox 1979:1:3-11
  14. Neuvonen PJ: Bioavailability of phenytoin. Clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinetics 1979:4:91-103
  15. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 1980, Lääketietokeskus, Helsinki, ss. 202-207.
  16. Neuvonen PJ: Farmakokinetiikan sovellutukset käytännön lääkehoitoon. Duodecim 1980:96:356-365
  17. Neuvonen PJ, Elonen E, Vilska J: Lääkehiili myrkytysten hoidossa. Suomen Lääkärilehti 1980:35:2861-2863
  18. Neuvonen PJ: Drug absorption interactions. In: Drug Absorption. The proceedings of the international conference on drug absorption (eds. Prescott, LF & Nimmo WS), Edinburg, Sept. 1979, Adis Press, 1981 pp 228-237
  19. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 1981, Lääketietokeskus, Helsinki, ss. 205-210.
  20. Neuvonen PJ, Elonen E, Vapaatalo H, Mattila MJ: Yleisiä näkökohtia myrkytyksistä, luku 76 oppikirjassa: Farmakologia ja toksikologia (Chapter “General aspects in poisonings” in the Textbook of Pharmacology and Toxicology, eds. Tuomisto and Paasonen) Kandidaattikustannus Helsinki, 1982: pp 843-859
  21. Elonen E, Neuvonen PJ, Vapaatalo H, Mattila MJ: Tärkeimmät lääkeainemyrkytykset, luku 77 oppikirjassa Farmakologia ja toksikologia (Chapter “The most important drug intoxications” in the Textbook of Pharmacology and Toxicology, eds. Tuomisto and Paasonen) Kandidaattikustannus Oy, Helsinki, 1982, pp 843-859
  22. Elonen E, Vapaatalo H, Neuvonen PJ, Mattila MJ: Alkoholin, liuottimien ja muiden teknokemian tuotteiden aiheuttamat myrkytykset, luku 78 oppikirjassa Farmakologia ja toksikologia (Chapter “Poisonings caused by alcohols, solvents and other technochemical products” in the Textbook of Pharmacology and Toxicology, eds. Tuomisto and Paasonen) Kandidaattikustannus Oy, Helsinki, 1982 pp 851-859
  23. Vapaatalo H, Mattila MJ, Elonen E, Neuvonen PJ: Häkämyrkytys, luku 79 oppikirjassa Farmakologia ja toksikologia (Chapter “Carbon monoxide poisoning” in the Textbook of Pharmacology and Toxicology, eds. Tuomisto and Paasonen) Kandidaattikustannus Oy, Helsinki, 1982 pp 861-862
  24. Neuvonen PJ: Diureetit, luku 41 oppikirjassa Farmakologia ja Toksikologia (Chapter Diuretis in the Textbook of Pharmacology and Toxicology, eds. Tuomisto and Paasonen) Kandidaattikustannus Oy, Helsinki 1982: pp 467-479
  25. Neuvonen PJ: Bioavailability of phenytoin: Clinical pharmacokinetic and therapeutics implications. Topics in Clinical Pharmacokinetics. 1982 vol I (eds. Gibaldi & Prescott) pp 24-38
  26. Neuvonen PJ, Clinical pharmacokinetics of oral activated charcoal in acute intoxications. Clin Pharmacokinet 1982:7:465-489
  27. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 1982, Lääketietokeskus, Helsinki, ss. 202-207.
  28. Tokola RA, Neuvonen PJ: Pharmacokinetics of antiepileptic drugs. Acta Neurol Scand 1983:68: suppl. 97:17-27
  29. Neuvonen PJ: Lääkehiili myrkytysten hoidossa. Activated charcoal in the treatment of poisonings (Editorial) Duodecim 1983:99:1506-1507
  30. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 1983, Lääketietokeskus, Helsinki, ss. 202-207.
  31. Neuvonen PJ: Lääkkeiden aiheuttamat munuaisvauriot. Leiraksen 28. luentopäivät lääkäreille, 1984: s 75-83
  32. Neuvonen PJ: Acute Poisoning. Use of oral activated charcoal. In “Drugs in dose and overdose. Recent Advances in Clinical Pharmacology and Toxicology”, Birmingham 1984: pp 48-49
  33. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 1984, Lääketietokeskus, Helsinki, ss. 184-189.
  34. Neuvonen PJ: Noninvasiiviset farmakokineettiset menetelmät myrkytysten hoidossa (Non-invasive pharmacokinetic methods in the treatment of intoxications). Vox 1985:7:101-110
  35. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 1985, Lääketietokeskus, Helsinki, ss. 192-197.
  36. Neuvonen PJ: Drug absorption interactions. A plenary lecture at the III World Conference on Clinical Pharmacology and Therapeutics (CPT 86), Stockholm, 27.7.-1.8.1986, Abstracts II, pp. 148- 149.
  37. Neuvonen PJ: Tarvittaisiinko Suomessa päivystävä lääkeinformaatiokeskus? (Is there need of a round-the-clock drug information center in Finland). Duodecim 1986:102:1634-1635.
  38. Neuvonen PJ: Clinical Pharmacology in Finland. Joint Meeting of Yogoslav and Finnish Pharmacologists. Dubrovnik, 24.-26.9.1986, p. 7
  39. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 1986, Lääketietokeskus, Helsinki, ss. 192-197.
  40. Neuvonen PJ: Vanhusten lääkehoidon erityispiirteet. “Vanhus ja sairaus”, 31. luentopäivät lääkäreille (Leiras-Medica) 1987, ss. 25-29.
  41. Neuvonen PJ: Lääkkeiden sivu- ja yhteisvaikutusten mekanismeista. Farmasian Päivät, 14.-15.11. 1987, Uusiutuva Farmasia, s. 124-127
  42. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 1987, Lääketietokeskus, Helsinki, ss. 198-203.
  43. Elonen E, Neuvonen PJ, Vapaatalo H, Mattila MJ: Tärkeimmät lääkeainemyrkytykset, luku 79 oppikirjassa Farmakologia ja Toksikologia (toim. Tuomisto ja Paasonen), 4. painos, Medicina Oy, Kuopio, 1988, ss. 867-873
  44. Elonen E, Vapaatalo H, Neuvonen PJ, Mattila MJ: Alkoholien, liuottimien ja muiden teknokemiallisten tuotteiden aiheuttamat myrkytykset, luku 80 oppikirjassa Farmakologia ja Toksikologia (toim. Tuomisto ja Paasonen), 4. painos, Medicina Oy, Kuopio, 1988, ss. 875-8
  45. Neuvonen PJ: Unilääkkeet ja rauhoittavat lääkeaineet, luku 26 oppikirjassa Farmakologia ja Toksikologia (toim. Tuomisto ja Paasonen), 4. painos, Medicina Oy, Kuopio, 1988, ss. 281-292
  46. Neuvonen PJ: Alkoholi, luku 27 oppikirjassa Farmakologia ja Toksikologia (toim. Tuomisto ja Paasonen), 4. painos, Medicina Oy, Kuopio, 1988, ss. 293-297
  47. Neuvonen PJ: Diureetit, luku 45 oppikirjassa Farmakologia ja Toksikologia (toim. Tuomisto ja Paasonen), 4. painos, Medicina Oy, Kuopio, 1988, ss. 493-504
  48. Neuvonen PJ: Eräitä kliinisen farmakologian peruskysymyksiä, luku 74 oppikirjassa Farmakologia ja Toksikologia (toim. Tuomisto ja Paasonen), 4. painos, Medicina Oy, Kuopio, 1988, ss. 819-826
  49. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 1988, Lääketietokeskus, Helsinki, ss. 197-202
  50. Neuvonen PJ, Elonen E, Vapaatalo H, Mattila MJ: Yleisiä näkökohtia myrkytyksistä, luku 78 oppikirjassa Farmakologia ja Toksikologia (toim. Tuomisto ja Paasonen), 4. painos, Medicina Oy, Kuopio, 1988, ss. 857-866
  51. Vapaatalo H, Mattila MJ, Elonen E, Neuvonen PJ: Häkämyrkytys, luku 81 oppikirjassa Farmakologia ja Toksikologia (toim. Tuomisto ja Paasonen), 4. painos, Medicina Oy, Kuopio, 1988, ss. 885-886
  52. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 1989, Lääketietokeskus, Helsinki, ss. 182-188
  53. Neuvonen PJ, Olkkola KT: Oral activated charcoal in the treatment of intoxications: Role of single and repeated doses. Medical Toxicology 1988:3:33-58.
  54. Neuvonen PJ, Kivistö K: The clinical significance of food-drug interactions: a review (asked by the A new and hazardous interaction between drugs.ournal). The Medical Journal of Australia 1989:150:36-40
  55. Olkkola KT, Neuvonen PJ: Treatment of intoxications using single and repeated doses of oral activated charcoal (A review asked by the journal). Journal de Toxicologie Clinique et Experimentale 1989:9:265-275
  56. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 1990, Lääketietokeskus, Helsinki, ss. 187-193
  57. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 1991, Lääketietokeskus, Helsinki, ss. 197-203
  58. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 1992, Lääketietokeskus, Helsinki, ss. 198-204
  59. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. L kevalmisteet Pharmaca Fennica 1993, Lääketietokeskus, Helsinki, ss. 203-10.
  60. Neuvonen PJ: Vanhus ja lääkkeet. Laboratoriokäsikirja ’93. Yhtyneet Laboratoriot, Helsinki 1992, s. 393-7.
  61. Neuvonen PJ: Mitä seikkoja lääkeainemääritysten tulkinnassa on otettava huomoon. Laboratoriok sikirja 94-95, ss. 400-4040. Otava, Keuruu 1993.
  62. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Lääkevalmisteet Pharmaca Fennica 1994, Lääketietokeskus, Helsinki, ss. 205-12.
  63. Mattila MJ, Neuvonen PJ: Kliininen toksikologia. Oikeuslääketieteen perusteet (toim. A Penttilä, J Hirvonen ja P Saukko), Duodecim, Helsinki 1993, ss. 264-274.
  64. Neuvonen PJ: Uudet, vaaralliset lääkeyhteisvaikutukset. Duodecim 1993: 20: 1833-9.
  65. Kivistö K, Lehto P, Neuvonen PJ: Fluorokinolonien yhteisvaikutukset toisten lääkeaineiden kanssa. Suomen Lääkärilehti. 1994: 49; 541-544
  66. Kivistö KT, Neuvonen PJ, Klotz U: Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences. (Leading article, asked by the journal) Clinical Pharmacokinetics 1994:27:1-5
  67. Himberg J-J, Neuvonen PJ: Lääkeaineiden farmakokineettisiä ominaisuuksia. Liite 3, ss. 751-758, kirjassa: Kliininen farmakologia (toim. Neuvonen ym., Kandidaattikustannus Oy 1994).
  68. Neuvonen PJ: Farmakokineettiset käsitteet ja niiden sovellutukset lääkehoitoon. Luku 1, ss. 1-10, kirjassa: Kliininen farmakologia (toim. Neuvonen ym., Kandidaattikustannus Oy 1994).
  69. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Luku 4, ss. 27-40, kirjassa: Kliininen farmakologia (toim. Neuvonen ym., Kandidaattikustannus Oy 1994).
  70. Neuvonen PJ: Lääkevahinkovakuutus, Myrkytystietokeskus. Luku 61, ss. 603-604, kirjassa: Kliininen farmakologia (toim. Neuvonen ym., Kandidaattikustannus Oy 1994).
  71. Neuvonen PJ. Luku “Psyykenlääkkeiden käytön yhteisvaikutukset”, ss. 239-251 kirjassa (toim. Achte & Tamminen) Käytännön moderni psykofarmakologia. (ISBN 951-9221-64-6), Recallmed Oy 1994.
  72. Neuvonen PJ, Elonen E, Perttunen K, Olkkola KT: Akuutit lääkemyrkytykset. Luku 64, ss. 617-632, kirjassa: Kliininen farmakologia (toim. Neuvonen ym., Kandidaattikustannus Oy 1994).
  73. Neuvonen PJ, Himberg J-J, Iisalo E, Mattila MJ, Ylitalo P (toim.): Kliininen farmakologia. (ISBN 951-8951-09-8) Kandidaattikustannus Oy, Helsinki 1994.
  74. Neuvonen PJ, Kivistö K: Enhancement of drug absorption by antacids – an unrecognized drug interaction. Clin Pharmacokinet 1994:27:120-128.
  75. Neuvonen P, Olkkola K, Klaukka T: Uutta tietoa midatsolaamin yhteisvaikutuksesta kalsiuminestäjien ja sienilääkkeiden kanssa. Suomen Lääkärilehti 1994:49;2084-5.
  76. Tilvis R, Neuvonen PJ, Iisalo E: Lääkehoidon erityispiirteet vanhuksilla. Luku 9, ss.67-78,kirjassa: Kliininen farmakologia (toim. Neuvonen ym., Kandidaattikustannus Oy 1994).
  77. Ylitalo P, Neuvonen PJ: Lääkeaineiden pitoisuusmittausten yleiset periaatteet, käyttömahdollisuudet ja merkitys. Luku 68,ss.653-658, kirjassa: Kliininen farmakologia (toim. Neuvonen ym., Kandidaattikustannus Oy 1994).
  78. Ylitalo P, Neuvonen PJ: Eri lääkeryhmien pitoisuusmittaukset. Luku 69, ss. 659-668, kirjassa: Kliininen farmakologia (toim. Neuvonen ym., Kandidaattikustannus Oy 1994).
  79. Kivistö KT, Neuvonen PJ: Bioavailability problems resulting from drug-metal ion interactions in the gastrointestinal tract. In Handbook of Metal-Ligand Interactions in Biological Fluids, Marcel Dekker, Inc., New York – Basel – Hong Kong (ed. G. Berthon) 1995 (ISBN 0-8247-9638-1), pp. 1432-1444.
  80. Neuvonen PJ: Interactions in first-pass metabolism and variability in drug response. In Clinical Measurement in Drug Evaluation”(eds. WS Nimmo and CT Tucker, John Wiley & Sons Ltd (ISBN 0 471 94391 6), pp. 301-313, 1995.
  81. Neuvonen PJ: Lääkeaineden haitalliset yhteisvaikutukset. Pharmaca Fennica 1996, ss.181-187, Kirjapaino Oy West Point, Rauma, 1995
  82. Neuvonen P: A new and hazardous interaction between drugs. Universitas Helsingiensis 1995:XIV:28-9.
  83. Elonen E, Olkkola KT, Neuvonen PJ: Alkoholien ja er iden teknokemiallisten tuotteiden aiheuttamat akuutit myrkytykset. Luku 81, ss.1023-1027, kirjassa “Farmakologia ja Toksikologia” (toim. Koulu ym., Medicina, Kuopio 1996)
  84. Elonen E, Olkkola KT, Neuvonen PJ: Häkämyrkytys. Luku 82, ss. 1029-1030, kirjassa “Farmakologia ja Toksikologia” (toim. Koulu ym., Medicina, Kuopio 1996)
  85. Mattila MJ & Neuvonen PJ: Lääkkeiden yhteisvaikutuksista. Iatrogeeniset sairaudet. Luku 75, ss.957-965, kirjassa “Farmakologia ja Toksikologia” (toim. Koulu, Tuomisto & Paasonen, Medicina, Kuopio 1996)
  86. Neuvonen PJ: Lääkeannos. Luku 3, ss.65-72, kirjassa “Farmakologia ja Toksikologia” (toim. Koulu ym., Medicina Kuopio 1996)
  87. Neuvonen PJ: Unilääkkeet. Luku 26, ss. 371-379, kirjassa “Farmakologia ja Toksikologia” (toim. Koulu ym., Medicina Kuopio 1996)
  88. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset, Kirjassa Pharmaca Fennica 1997 I, ss. 187-193. Kirjapaino Oy West Point, Rauma 1996
  89. Neuvonen P, Kivistö K: A-influenssa tuli – älä unohda amantadiinia! Suomen Lääkärilehti 1996:96:177-8.
  90. Neuvonen PJ, Ruosteenoja R: Verenpainelääkkeiden yhteisvaikutukset. Käytännön Lääkäri 1996:39:35-39
  91. Neuvonen PJ, Seppälä T: Alkoholi. Luku 27, ss. 381-385, kirjassa “Farmakologia ja Toksikologia” (toim. Koulu ym., Medicina, Kuopio 1996)
  92. Neuvonen PJ: Diureetit. Luku 43, ss.577-588, kirjassa “Farmakologia ja Toksikologia” (toim. Koulu ym., Medicina Kuopio 1996)
  93. Neuvonen PJ: Eräitä kliinisen farmakologian peruskysymyksiä. Luku 74, ss.951-956, kirjassa “Farmakologia ja Toksikologia” (toim. Koulu ym., Medicina, Kuopio 1996)
  94. Neuvonen PJ, Elonen E, Olkkola KT: Yleisiä näkökohtia akuuteista myrkytyksistä. Luku 79, ss. 1003-1013, kirjassa “Farmakologia ja Toksikologia” (toim. Koulu ym., Medicina, Kuopio 1996)
  95. Olkkola KT, Neuvonen PJ, Elonen E: Tärkeimmät lääkeainemyrkytykset. Luku 80, ss. 1015-1022, kirjassa “Farmakologia ja Toksikologia” (toim. Koulu ym., Medicina, Kuopio 1996)
  96. Tuomisto J, Neuvonen PJ: Farmakokinetiikka. Luku 4, ss. 74-92, kirjassa “Farmakologia ja Toksikologia” (toim. Koulu ym., Medicina, Kuopio 1996)
  97. Kivistö KT, Kinos M, Neuvonen PJ: Antidootit myrkytysten hoidossa. Suomen Lääkärilehti 1997:52:963-72
  98. Suhonen R, Neuvonen PJ: The tolerability profile of terbinafine. Reviews in Contemporary Pharmacotherapy. 1997:8: 363-372.
  99. Suhonen R, Neuvonen PJ, Palva E: Uusien sienilääkkeiden teho ja turvallisuus – ihon ja kynsien sienitautien sisäinen hoito. Suomen Lääkärilehti 1997:52:2273-9.
  100. Kivistö KT, Neuvonen PJ: Yhteisvaikutukset lääkkeiden imeytymisessä. Suomen Lääkärilehti 1997:52:2967-9.
  101. Kivistö KT, Vilska J, Neuvonen PJ: Lääkehiili riittää useimmiten imeytymisen estämiseksi akuuteissa myrkytyksissä. Suomen Lääkärilehti 1997:52:3879-83.
  102. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 1998 II, ss. 1-7. Kirjapaino Oy West Point Rauma 1997. ISSN 0355-7472.
  103. Neuvonen P: Lääkkeet ja alkoholi. Sivut 382-86 kirjassa Päihdelääketiede (toim. Salaspuro M, Kiianmaa K ja Seppä K) Duodecim 1998
  104. Neuvonen P: Alkoholimyrkytys. Sivut 259-64 kirjassa Päihdelääketiede (toim. Salaspuro M, Kiianmaa K ja Seppä K) Duodecim 1998
  105. Neuvonen PJ, Ylitalo P: Mihin kliinistä farmakologiaa tarvitaan (pääkirjoitus). Duodecim 1998:10:7- 8.
  106. Neuvonen PJ, Kivistö K: Lääkeaineiden ongelmalliset yhteisvaikutukset. Duodecim 1998:10:89-98.
  107. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 1999 I, Asiantuntija- artikkelit, ss. 1-7.
  108. Backman JT, Kivistö KT, Wang J-S, Neuvonen PJ: Antifungals. Chapter 47 in the book Metabolic Drug Interactions (eds. Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M), pp. 623- 646, 2000 (Lippincott Williams & Wilkins)
  109. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 2000 III, Asiantuntija- artikkelit, ss. 3-10.
  110. Neuvonen PJ, Hoppu K: Kliininen toksikologia. Kirjassa Oikeuslääketiede (toim. A Penttilä J, Hirvonen, P Saukko ja PJ Karhunen. Duodecim (Karisto Oy Hämeenlinna) 2000, ss. 370-382.
  111. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 2001 III, Asiantuntija-artikkelit, ss. 3-10, Lääketietokeskus Oy, Kirjapaino West Point, Rauma 2000.
  112. Elonen E, Olkkola KT, Neuvonen Pertti J: Alkoholien ja eräiden teknokemiallisten tuotteiden aiheuttamat akuutit myrkytykset. Kirjassa Farmakologia ja toksikologia (toim. M.Koulu ja J.Tuomisto) Kustannusosakeyhtiö Medicina 2001, ss.1047-1052.
  113. Kivistö Kari T, Neuvonen Pertti J: Farmakokinetiikka. Kirjassa Farmakologia ja toksikologia (toim. M.Koulu ja J.Tuomisto) Kustannusosakeyhtiö Medicina 2001, ss.75-94.
  114. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 2002 III, ss. 3-10. Kirjapaino Oy West Point, Rauma 2001.
  115. Neuvonen PJ: Lääkeannos. Kirjassa Farmakologia ja toksikologia (toim. M.Koulu ja J.Tuomisto) Kustannusosakeyhtiö Medicina 2001, ss.67-74.
  116. Neuvonen PJ: Lääkkeiden yhteisvaikutukset. Kirjassa Farmakologia ja toksikologia (toim. M.Koulu ja J.Tuomisto) Kustannusosakeyhtiö Medicina 2001, ss.987-994.
  117. Neuvonen PJ: Diureetit. Kirjassa Farmakologia ja toksikologia (toim. M.Koulu ja J.Tuomisto) Kustannusosakeyhtiö Medicina 2001, ss.557-566.
  118. Neuvonen PJ: Eräitä kliinisen farmakologian peruskysymyksiä. Kirjassa Farmakologia ja toksikologia (toim. M.Koulu ja J.Tuomisto) Kustannusosakeyhtiö Medicina 2001, ss.981-986.
  119. Neuvonen PJ, Elonen E, Olkkola KT: Yleisiä näkökohtia akuuteista myrkytyksistä. Kirjassa Farmakologia ja toksikologia (toim. M.Koulu ja J.Tuomisto) Kustannusosakeyhtiö Medicina 2001, ss.1029-1038.
  120. Olkkola KT, Neuvonen PJ, Elonen E: Tärkeimmät lääkeainemyrkytykset. Kirjassa Farmakologia ja toksikologia (toim. M.Koulu ja J.Tuomisto) Kustannusosakeyhtiö Medicina 2001, ss.1039-1047.
  121. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 2003 III, ss. 2643- 2648. Kirjapaino Oy West Point, Rauma 2002.
  122. Neuvonen PJ.: Farmakokinetiikan käsiteet ja sovellutukset lääkehoitoon. Kirjassa Kliininen farmakologia ja lääkehoito (toim. PJ Neuvonen, J-J Himberg, R. Huupponen, KT Kivistö, P Ylitalo) Kandidaattikustannus Oy 2002, ss.14-26.
  123. Neuvonen PJ.: Lääkeaineiden haitalliset yhteisvaikutukset. Kirjassa Kliininen farmakologia ja lääkehoito (toim. PJ Neuvonen, J-J Himberg, R. Huupponen, KT Kivistö, P Ylitalo) Kandidaattikustannus Oy 2002, ss.45-62.
  124. Neuvonen PJ, Kivistö Kari T, Olkkola KT: Akuutit lääkemyrkytykset. Kirjassa Kliininen farmakologia ja lääkehoito (toim. PJ Neuvonen, J-J Himberg, R. Huupponen, KT Kivistö, P Ylitalo) Kandidaattikustannus Oy 2002, ss. 839-857.
  125. Tilvis R, Neuvonen Pertti J: Lääkehoidon erityispiirteet vanhuksilla. Kirjassa Kliininen farmakologia ja lääkehoito (toim. PJ Neuvonen, J-J Himberg, R. Huupponen, KT Kivistö, P Ylitalo) Kandidaattikustannus Oy 2002, ss.100-113.
  126. Ylitalo P, Neuvonen Pertti J: Lääkeaineiden pitoisuusmittausten yleiset periaatteet, käyttömahdollisuudet ja merkitys. Kirjassa Kliininen farmakologia ja lääkehoito (toim. PJ Neuvonen, J-J Himberg, R. Huupponen, KT Kivistö, P Ylitalo) Kandidaattikustannus Oy 2002, ss. 886-891.
  127. Ylitalo P, Neuvonen PJ, Kivistö Kari T: Eri lääkeaineryhmien pitoisuusmittaukset. Kirjassa Kliininen farmakologia ja lääkehoito (toim. PJ Neuvonen, J-J Himberg, R. Huupponen, KT Kivistö, P Ylitalo) Kandidaattikustannus Oy 2002, ss. 892-904.
  128. Neuvonen P: Kliininen farmakologia (Farmakokinetiikka, Lääkkeiden haittavaikutukset, Haitalliset lääkeyhteisvaikutukset). Kirjassa Therapia Odontologica, Hammaslääketieteen käsikirja (toim. Jukka H.Meurman, Heikki Murtomaa, Yrsa Le Bell, Heikki Autti) Academica-Kustannus Oy, Helsinki 2003, ss. 245-263.
  129. Neuvonen P: Alkoholimyrkytykset. Kirjassa Päihdelääketiede (toim. Mikko Salaspuro, Kalervo Kiianmaa, Kaija Seppä) Kustannus Oy Duodecim 2003, ss. 287-292.
  130. Neuvonen P: Lääkkeet ja alkoholi. Kirjassa Päihdelääketiede (toim. Mikko Salaspuro, Kalervo Kiianmaa, Kaija Seppä) Kustannus Oy Duodecim 2003, ss. 413-417.
  131. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 2004 III, ss. 2785- 2790. Painoyhtymä Oy, Loviisa 2003.
  132. Niemi M, Backman J, Fromm MF, Neuvonen P, Kivistö K: Pharmacokinetic interactions with rifampicin: Clinical relevance. Clin Pharmacokinetics 2003;42:819-50.
  133. Paakkari I, Rauhala P, Backman J, Neuvonen P: Farmakologian ja kliinisen farmakologian opetus Helsingin yliopiston lääketieteellisessä tiedekunnassa. Suomen Lääkärilehti 2003;58:1048-1050.
  134. Jaakkola T, Backman J, Niemi M, Neuvonen P: Aikuistyypin diabeteksen lääkehoitoon liittyvät haitalliset yhteisvaikutukset. Suomen Lääkärilehti 2004;59:4237-4242.
  135. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 2005 I, ss. 587-993. Painoyhtymä Oy, Loviisa 2004.
  136. Neuvonen PJ, Tilvis R: Diureetit ovat eturivin verenpainelääkkeitä. Suomen Lääkärilehti 2005:60:2348-2351.
  137. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 2006 I, ss. 620-626. Lääketietokeskus Oy, Helsinki, 2005.
  138. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 2007 I, ss. 703-709. Lääketietokeskus Oy, Helsinki, 2007.
  139. Neuvonen PJ, Niemi M, Backman JT: Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clin Pharmacol Ther 2006:80:565-81.
  140. Neuvonen PJ, Backman JT, Niemi M: Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and atorvastatin. Clinical Pharmacokinetics 2008:47:463- 74.
  141. Backman J, Joutsi-Korhonen L, Neuvonen P, Lassila R: CYP2C9- ja VKORC1-geenitestit apuna oraalisen antikoagulanttihoidon toteuttamisessa. Duodecim 2008:124:1283-1288.
  142. Raaska K, Neuvonen P, Backman J: CYP2D6-geenitesti masennuslääkityksen yhteydessä. Duodecim 2008:124:1289-1293.
  143. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 2008 I, ss. 545-552. Lääketietokeskus Oy, Helsinki 2008.
  144. Jaakkola T, Backman J, Palva E, Neuvonen P: CYP1A2-estäjien, mm. siprofloksasiinin ja fluvoksamiinin aiheuttamat lääkeinteraktiot. Suomen Lääkärilehti 2009:64:3866-3869.
  145. Neuvonen P. Nuoren tutkijan palkinto Mikko Niemelle. Duodecim 2009:125:71-72.
  146. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 2009 I, ss. 581-587. Lääketietokeskus Oy, Helsinki 2009.
  147. Neuvonen PJ: Drug interactions with HMG-CoA reductase inhibitors (statins): The importance of CYP enzymes, transporters and pharmacogenetics. Current Opinion in Investigational Drugs 2010:11:323-332.
  148. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 2010 I, ss. 664-670. Lääketietokeskus Oy, Helsinki 2010.
  149. Kalliokoski A, Neuvonen PJ, Niemi M: SLCO1B1 polymorphism and oral antidiabetic drugs. Basic & Clinical Pharmacology & Toxicology 2010:107:775-781.
  150. Lilja J, Ylitalo P, Neuvonen PJ: Lääkeaineet ja myrkytykset. Kirjassa Laboratoriolääketiede Kliininen kemia ja hematologia, luku 30 (toim. Onni Niemelä ja Kari Pulkki) Kandidaattikustannus Oy, Helsinki 2010, s. 339-349.
  151. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 2011 I, ss. 667-673. Lääketietokeskus Oy, Helsinki 2011.
  152. Niemi M, Pasanen MK, Neuvonen PJ: Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacological Reviews 2011:63:157-181.
  153. Neuvonen PJ: Farmakokinetiikan käsitteet ja sovellutukset lääkehoitoon. Kirjassa Kliininen farmakologia ja lääkehoito, luku 1 (toim. Pertti J. Neuvonen, Janne T. Backman, Jaakko-Juhani Himberg, Risto Huupponen, Tapani Keränen ja Kari T. Kivistö) Kandidaattikustannus Oy, Helsinki 2011, s. 19-30.
  154. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Kirjassa Kliininen farmakologia ja lääkehoito, luku 4 (toim. Pertti J. Neuvonen, Janne T. Backman, Jaakko-Juhani Himberg, Risto Huupponen, Tapani Keränen ja Kari T. Kivistö) Kandidaattikustannus Oy, Helsinki 2011, s. 49-66.
  155. Tilvis R, Neuvonen PJ ja Pitkälä K: Lääkehoidon erityisppiirteet vanhuksilla. Kirjassa Kliininen farmakologia ja lääkehoito, luku 9 (toim. Pertti J. Neuvonen, Janne T. Backman, Jaakko-Juhani Himberg, Risto Huupponen, Tapani Keränen ja Kari T. Kivistö) Kandidaattikustannus Oy, Helsinki 2011, s. 123-137.
  156. Neuvonen PJ, Kivistö KT, Olkkola KT: Akuutit lääkemyrkytykset. Kirjassa Kliininen farmakologia ja lääkehoito, luku 68 (toim. Pertti J. Neuvonen, Janne T. Backman, Jaakko-Juhani Himberg, Risto Huupponen, Tapani Keränen ja Kari T. Kivistö) Kandidaattikustannus Oy, Helsinki 2011, s. 913- 929.
  157. Vakkilainen J, Backman JT, Himberg J-J, Neuvonen PJ: Lääkeaineiden farmakokineettisiä ominaisuuksia. Kirjassa Kliininen farmakologia ja lääkehoito, liite 2 (toim. Pertti J. Neuvonen, Janne T. Backman, Jaakko-Juhani Himberg, Risto Huupponen, Tapani Keränen ja Kari T. Kivistö) Kandidaattikustannus Oy, Helsinki 2011, s. 1021-1032.
  158. Neuvonen PJ: Yhdistelmävalmisteet – terapeuttisia innovaatioita vai kaupallisia jippoja? Suomen Lääkärilehti 2011: 33: 2348-2350.
  159. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 2012 I, ss. 698-704. Lääketietokeskus Oy, Helsinki 2012.
  160. Neuvonen PJ: Towards safer and more predictable drug treatment – Reflections from studies of the first BCPT Prize awardee. Basic & Clinical Pharmacology & Toxicology 2012:10:207-218.
  161. Neuvonen PJ: Diureetit. Kirjassa Farmakologia ja Toksikologia, luku 36 (toim. Markku Koulu, Eero Mervaala ja Jouko Tuomisto), 8. uudistettu painos, Kustannusyhtiö Medicina, Kuopio 2012, s. 611- 621.
  162. Neuvonen PJ: Eräitä kliinisen farmakologian peruskysymyksiä. Kirjassa Farmakologia ja Toksikologia, luku 65 (toim. Markku Koulu, Eero Mervaala ja Jouko Tuomisto), 8. uudistettu painos, Kustannusyhtiö Medicina, Kuopio 2012, s. 1075-1080.
  163. Neuvonen PJ: Lääkkeiden yhteisvaikutukset. Kirjassa Farmakologia ja Toksikologia, luku 66 (toim. Markku Koulu, Eero Mervaala ja Jouko Tuomisto), 8. uudistettu painos, Kustannusyhtiö Medicina, Kuopio 2012, s. 1081-1086.
  164. Tornio A, Niemi M, Neuvonen PJ, Backman JT: Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Trends in Pharmacological Sciences 2012:33(6):312-322.
  165. Neuvonen PJ: Lääkkeiden yhteisvaikutukset ovat yleensä hallittavissa. SIC! 2012:3:36-41.
  166. Neuvonen PJ: Vakavien lääkehaittojen ja vaarallisten lääkeinteraktioiden ennakointi ja ehkäisy. Duodecim 2013:129:22-30.
  167. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 2013 I, 750-756. Lääketietokeskus Oy, Helsinki 2013.
  168. Neuvonen PJ: Diureetit. Kirjassa Farmakologia ja Toksikologia, luku 36 (toim. Markku Koulu ja Eero Mervaala, 9. uudistettu painos, Kustannusyhtiö Medicina, Kuopio 2013, s. 611-621.
  169. Neuvonen PJ: Eräitä kliinisen farmakologian peruskysymyksiä. Kirjassa Farmakologia ja Toksikologia, luku 65 (toim. Markku Koulu ja Eero Mervaala), 9. uudistettu painos, Kustannusyhtiö Medicina, Kuopio 2013, s. 1075-1080.
  170. Neuvonen PJ: Lääkkeiden yhteisvaikutukset. Kirjassa Farmakologia ja Toksikologia, luku 66 (toim. Markku Koulu ja Eero Mervaala), 9. uudistettu painos, Kustannusyhtiö Medicina, Kuopio 2013, s. 1081-1086.
  171. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 2014 I, 798-804. Lääketietokeskus Oy, Helsinki 2014.
  172. Neuvonen PJ: Tietämys lääkeyhteisvaikutuksista on lisääntynyt huikeasti. SIC! Lääketietoa Fimeasta 2014 Nro 2: 26-29.
  173. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 2015 I, 833-838. Lääketietokeskus Oy, Helsinki 2015.
  174. Backman JT, Filppula AM, Niemi M, Neuvonen PJ: Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacological Reviews 2016:68(1):168-241.
  175. Puustinen J, Lähteenmäki R, Neuvonen PJ, Kivelä SL: Miten vieroittaa iäkäs potilas unilääkkeestä? Palstalla ”Tieteessä/katsaus”, Suomen Lääkärilehti 2016:71(18):1303-7.
  176. Puustinen J, Lähteenmäki R, Neuvonen PJ, Kivelä SL: Withdrawing older people from benzodiazepine hypnotics. English summary. Suomen Lääkärilehti 2016:71(18):1307a.
  177. Puustinen J, Lähteenmäki R, Neuvonen PJ, Kivelä SL: Unilääkevieroituksesta saatiin hyviä tuloksia Satauni-projektissa. Palstalla ”Työssä/raportti”, Suomen Lääkärilehti 2016:71(18)1324-5.
  178. Neuvonen PJ: Lääkeaineiden haitalliset yhteisvaikutukset. Pharmaca Fennica 2016 I, 1077-82. Lääketietokeskus Oy, Helsinki 2016 (ISSN 0355-7472).
  179. Höjer J, Jacobsen D, Neuvonen PJ, Rosenberg PH: Lipid rescue – efficacy and safety still unproven. Basic & Clinical Pharmacology & Toxicology 2016:119:345-348.
  180. Tornio A, Neuvonen PJ, Niemi M, Backman JT: Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters. Expert Opinion on Drug Metabolism and Toxicology 2016 Aug. 31:1-13 (epub)
  181. Neuvonen PJ: Eräitä kliinisen farmakologian peruskysymyksiä. Kirjassa Farmakologia ja Toksikologia, luku 65 (toim. Markku Koulu ja Eero Mervaala), 10. uudistettu painos, Kustannusyhtiö Medicina, Kuopio 2016.
  182. Neuvonen PJ: Lääkkeiden yhteisvaikutukset. Kirjassa Farmakologia ja Toksikologia, luku 66 (toim. Markku Koulu ja Eero Mervaala), 10. uudistettu painos, Kustannusyhtiö Medicina, Kuopio 2016.

download complete list of publications

[/wm_item][/wm_tabs][/vc_column][/vc_row]